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ABSTRACT

Redan, Benjamin W. Ph.D., Purdue University, August 2016. Intestinal Adaptation to
Repeated Exposure of Flavonoid-rich Foods: In Vitro and In Vivo Data. Major Professor:
Mario Ferruzzi.

Interest in application of flavonoids for chronic disease prevention has grown
significantly, but the low oral bioavailability of these compounds from acute doses is
commonly highlighted as a limitation when considering their biological significance. Still,
the impact of broad dietary patterns such as repeated exposure on flavonoid’s
absorption, metabolism, and eventual efficacy is critical to consider since evidence
suggests that their bioavailability may be enhanced with repeated exposure. To fill this
gap in knowledge, this dissertation will focus on three major areas including
characterization of flavonoid metabolites, in addition to use of in vitro models and
clinical work to test the effect of repeated exposure on flavonoid bioavailability.
Though flavan-3-ols undergo Phase II metabolism in humans and rodents,
researchers have generally not been able to utilize fully characterized standards for
these metabolites. Thus, collaborators synthesized flavan-3-ols metabolites after which
liquid chromatography/time-of-flight mass spectrometry (LC-TOF-MS) and nuclear
magnetic resonance (NMR) spectroscopy were used to characterize their structure and
match the synthesized metabolites to those found in rodent plasma. To explore changes

xvi
occurring in the upper small intestine from flavonoid repeated exposure, Caco-2 cells
were differentiated in the presence of isolated flavan-3-ols, green tea, grape seed, or
blackberry extracts. EGCG and EC pretreatment altered formation rate of Phase II
metabolites, in addition, green tea and grape seed extract pretreatment both resulted in
increased flavan-3-ol transport. In contrast, blackberry extract pretreated monolayers
displayed decreased transport of phenolic compounds. Finally, alterations in mRNA
expression of select transport and metabolizing genes were observed in cells pretreated
with blackberry extract. To determine if flavonoid absorption changes with repeated
exposure to blackberry in humans, a controlled feeding study was performed to assess
the effect of three-week daily blackberry exposure on flavonoid pharmacokinetics. The
results showed increased plasma AUC of peonidin glucoside after blackberry treatment
in lean volunteers. Accumulation of total anthocyanins in urine was greater in the lean
group after blackberry exposure. This difference may be driven by increased Phase II
anthocyanin metabolites since there was greater accumulation of anthocyanin
metabolites in urine in the lean group after blackberry exposure.
Taken together, these data suggest that the small intestine may be a key
regulator of the observed adaptive phenomena occurring in vivo. These results
demonstrate that there is both differential transport, absorption, and metabolism of
flavonoids, including select flavonoids and phenolic acids, after repeated exposure to
flavonoid-rich blackberry and that this response appears to differ with BMI. These
studies provide a basis for future work on the effect of chronic flavonoid exposure on
their bioavailability and metabolism in a range of interventions.
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CHAPTER 1.

REVIEW OF THE LITERATURE

As part of the manuscript “Altered Transport and Metabolism of Phenolic Compounds in
Obesity and Diabetes: Implications for Functional Food Development and Assessment,”
BW Redan1, JA Novotny2, and MG Ferruzzi1,3, in review, Advances in Nutrition.
1

Department of Nutrition Science, Purdue University, 2USDA-ARS Beltsville Human
Nutrition Research Center, 3Department of Food Science, Purdue University

1.1

Introduction

Plant-derived phenolic compounds are a subclass of phytochemicals characterized
by the presence of one or more phenol moieties, and their consumption is associated
with a reduced risk of chronic disease. While evidence has primarily been drawn from
the epidemiological associations between foods rich in phenolics and disease-risk
outcomes (Zamora-Ros et al., 2013a), data from in vitro studies (Tenore et al., 2013),
animal models (Tian et al., 2013), and more crucially clinical trials have begun to
substantiate these epidemiological associations (Hooper et al., 2012). While results are
not fully conclusive (Jia et al., 2010), these data generally support the notion that plant-

2
derived phenolic compounds likely impart benefits to humans. As a result, desire to
expand application of phenolic compounds as a disease-preventative agent is gaining
momentum, in part, due to the cost-effective nature of dietary prevention strategies
relative to therapeutic approaches. This concept has been translated into formulation of
phenolic compounds in functional foods and dietary supplements for the broader public.
Plant-derived phenolic compounds are a subclass of phytochemicals characterized
by the presence of one or more phenol moieties, and their consumption is associated
with a reduced risk of chronic disease. While evidence has primarily been drawn from
the epidemiological associations between foods rich in phenolics and disease-risk
outcomes (Zamora-Ros et al., 2013a), data from in vitro studies (Tenore et al., 2013),
animal models (Tian et al., 2013), and more crucially clinical trials have begun to
substantiate these epidemiological associations (Hooper et al., 2012). While results are
not fully conclusive (Jia et al., 2010), these data generally support the notion that plantderived phenolic compounds likely impart benefits to humans. As a result, desire to
expand application of phenolic compounds as a disease-preventative agent is gaining
momentum, in part, due to the cost-effective nature of dietary prevention strategies
relative to therapeutic approaches. This concept has been translated into formulation of
phenolic compounds in functional foods and dietary supplements for the broader public.
Phenolic compounds can be broadly divided into flavonoid and non-flavonoid
derivatives (Del Rio et al., 2013) (see Figure 1). The flavonoid class encompasses six
major subclasses, each consisting of a three ring structure designated as A, B, and C. The
main subclasses are flavonols, flavones, isoflavones, flavanones, anthocyanins, and

3
flavan-3-ols, which are all considered polyphenols because of their multiple phenol
moieties. The flavan-3-ol (-)-epicatechin, which is found in high amounts in cocoa, grape
seed, and to a lesser extent in apples and tea, has received particular attention due to is
presence in high quantities in certain chocolates combined with chocolate’s general
popularity. Non-flavonoid phenolics include phenolic acids, stilbenoids, and lignins. One
of the most common dietary non-flavonoids is the phenolic acid gallic acid, present in
grapes and other fruits. Phenolic compounds naturally occur in either free or
glycosylated forms (Del Rio et al., 2013), which is significant since the glycoside addition
can modulate the solubility, chemistry, and bioavailability of individual phenolic
compounds (Murota et al., 2010; Okabe et al., 2011).

4

Figure 1. Flowchart of the main classes of phenolics with key examples of their chemical structure.
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The phenolic contents of common foods and beverages have been systematically
reviewed and documented in several publically available databases, including USDA’s
Nutrient Data Laboratory Flavonoid Database and INRA’s Phenol-Explorer (Bhagwat et
al.; Gu et al., 2004; Neveu et al., 2010; Pérez-Jiménez et al., 2010a, 2010b). The
predominate dietary sources of phenolics in the Western diet are generally accepted to
be fruits, vegetables, tea, wine, and cocoa products, with mean dietary intakes for
flavonoids ranging from a low of approximately 250 mg/day for U.S. adults (Sebastian et
al., 2015), 250-300 mg/day for Greek men and women (Zamora-Ros et al., 2015), 320
mg/day for Korean adults (Jun et al., 2016), to a high of 1,000 mg/day for British adult
populations (Zamora-Ros et al., 2015).
The diverse mechanisms proposed for the biological activities of phenolic
compounds are dependent on their structure and cellular target. Regardless of the
structure, dietary source of the phenolic compound, or specific mechanism by which it
may impart its biological activity, the ultimate efficacy of dietary phenolics is dependent
on the ability of the compounds to be absorbed intact or as a biologically relevant
metabolite, and then transported to target tissues where they can exert their biological
activity (Ferruzzi, 2010). The bioavailability of phenolics is therefore a critical factor to
consider when evaluating the efficacy of a food/supplement or designing products for
at-risk populations. In addition to these factors, disease states such as obesity or
diabetes that are common in industrialized countries (Malik et al., 2013) can impact the
bioavailability of nutrients and potentially phytochemicals (Xiao and Högger, 2014),
which may be related to the ability of these diseases to modulate gut function (Horowitz
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et al., 2002; Meyer-Gerspach et al., 2014), alter regulation of xenobiotic metabolizing
enzymes (Xiao and Högger, 2014), or perturb the gut microbial community critical to the
metabolism of phenolics (Hartstra et al., 2015).
This review will specifically focus on the effect of obesity and diabetes on the
bioavailability and bioactivity of dietary phenolics. Some outstanding questions on
absorption and metabolism of phenolic compounds include: (1) Why are phenolic
compounds potentially more effective in improving physiological conditions in individuals
who are lean or non-diabetic? (2) Are the absorption, metabolism, and transport of
phenolic compounds altered in individuals with obesity or diabetes? (3) If so, what
mechanism may be effective to target in order to increase biological activity of phenolic
compounds in obese or diabetic individuals?

1.2

Overview of the Absorption, Metabolism, and Transport of Phenolic Compounds
Preventative or therapeutic potential of phenolic compounds is highly dependent

on their ability to reach target tissues in a form that can exert biological function.
Multiple steps in this process include absorption, metabolism, and transport, in both the
upper and lower gastrointestinal tract (Neilson and Ferruzzi, 2011) (Summarized in
Figure 2). The first key step in the absorptive process is the release of phenolics from
the plant/food matrix into the soluble and bioaccessible fraction in the gut lumen.
Soluble phenolic forms are then actively and passively transported from the lumen into
the enterocyte, but then can be effluxed back out into the lumen by the action of ATPbinding cassette (ABC) transporters. Within the enterocyte, phenolics may also be
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metabolized prior to transport across the serosal side and into the portal vein for
circulation to the liver, where further metabolism may occur prior to systemic
circulation, excretion into bile/urine, or distribution to other tissues. Unabsorbed
phenolics or those secreted back into the gut lumen are carried to the lower gut and
made available to microbiota for catabolism into low molecular weight compounds,
including several previously characterized phenolic metabolites (Calani et al., 2012).
Since the broader aspects of absorption, metabolism and target tissue profiles have
been the subject of several reviews (Clifford et al., 2013; Del Rio et al., 2010, 2013;
Manach et al., 2005; Williamson and Manach, 2005), below are only key aspects of this
process, focusing on upper intestinal absorption and metabolism as they rely on both
inducible and non-inducible systems (Croom, 2012) that may be impacted by both
health status and previous exposure to phenolics. Factors in addition to the
metabolizing systems that are potentially affected by disease state, such as gut
microbiota, will not be covered extensively but will be discussed in a later section.

8
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Figure 2. Schematic of the key molecular processes involved in the transport and metabolism of (poly)phenolic compounds (PP).
PP-M, (poly)phenolic metabolites; MCT1, monocarboxylate transporter1; SGLT1, sodium dependent glucose transporter 1; P-gp,
P-glycoprotein; Phase II, Phase II metabolizing enzymes; MRP3, multidrug-resistance protein 3; solid arrow, pathway of native
phenolic compounds; dashed arrow, pathway of phenolic metabolites.
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1.3

Absorption of Phenolic Compounds

Absorption of phenolics in their dietary forms generally takes place in the small
intestine, although select phenolics may be absorbed in the stomach (anthocyanins) and
extensively in the lower intestine/colon (products of microbial catabolism). Uptake from
the intestinal lumen by enterocytes can occur for either the glycoside or aglycone forms
of phenolics (Del Rio et al., 2013). Glycosides of many phenolic compounds are thought
to be translocated from the gut lumen to the enterocyte by transporters, including
sodium-dependent glucose transporter 1 (SGLT1) and glucose transporter 2 (GLUT2).
Since glycosidic forms are effluxed back into the intestinal lumen after uptake by the
enterocyte (Del Rio et al., 2013), absorption efficiency is believed to be increased by first
hydrolyzing the carbohydrate moiety attached to O-linked compounds through the
action of enzymes produced the intestinal brush border or those synthesized by gut
microbiota. The aglycone form of phenolics can then enter the enterocyte through
active uptake by transporters such as monocarboxylate transporter 1 (MCT1) or to a
certain extent by passive diffusion (Vaidyanathan and Walle, 2003). Once within the
enterocyte, phenolics can then be metabolized (described below) or effluxed back into
the intestinal lumen by transporters such as multidrug resistance-associated protein 1
or 2 (MRP1/2).

1.4

Metabolism of Phenolic Compounds

Phenolics are largely transformed and transported via xenobiotic metabolizing
systems expressed extensively in intestinal and hepatic tissues (Lampe and Chang, 2007),
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but also in other tissues and compartments including the blood-brain barrier (CamposBedolla et al., 2014; Ouzzine et al., 2014). Absorbed phenolic compounds undergo Phase
II conjugation to produce metabolites that are less chemically reactive and either more
hydrophilic or hydrophobic compared to the parent compound, thereby facilitating
transport processes leading to excretion by the Phase III system through bile/feces or
urine (see Figure 3). Since the extent to which individual phenolics are biotransformed
may result in alteration of specific biological activity (Lambert et al., 2007; Monagas et
al., 2010; Spencer et al., 2004), factors that ultimately affect metabolism of phenolics
are believed to have significant impact on their potential to exert protective therapeutic
effects at target tissues.
The methylation of phenolics driven by catechol-O-methyltransferase (COMT)
results in a more hydrophobic and less chemically reactive species (Croom, 2012). This
increased hydrophobicity may then increase the association of phenolics with key
transporters on the cell membrane, altering their transport across the enterocyte or
other cell types (Walle, 2007), leading to the potential for accumulation of methylated
derivatives in certain tissues such as brain (Chen et al., 2015; Ferruzzi et al., 2009; Wang
et al., 2012). However, methylation generally decreases phenolic antioxidant capacity in
vitro (Dueñas et al., 2010; Ishimoto et al., 2012) and thus may also affect bioactivity. For
example, while methylation of the tea flavan-3-ol epigallocatechin-3-gallate (EGCG)
impairs its ability to decrease tumor proliferation (Lambert et al., 2007), the flavone
chrysin has greater anti-inflammatory ability in the human intestinal cell line Caco-2
when methylated (During and Larondelle, 2013). In contrast, methylated epicatechin
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glucuronide derivatives were observed to have greater ability to enhance long-term
potentiation in hippocampal slices relative to simple glucuronides (Wang et al., 2012).
The effect of the methylation transformation on bioactivity is a subject of significant
debate and appears to be specific to the class of phenolic being metabolized.
Sulfotransferases (SULT) conjugate anionic sulfate groups to phenolic moieties to
produce a more hydrophilic species (Peters et al., 1990), resulting in either a more or
less bioactive species depending on the cellular target (Zhang et al., 2004). For example,
sulfate metabolites of the grape phenolic resveratrol, in contrast to the resveratrol
aglycone and its glucuronide, are not effective in decreasing lipid content of
differentiated adipocytes, while sulfate metabolites have been reported to be effective
in decreasing lipid content of maturing adipocytes (Lasa et al., 2012).
Glucuronidation conjugates glucuronic acid to phenolic compounds through the
action of UDP-glucuronyl transferase (UGT) to yield a more hydrophilic species that can
be efficiently eliminated (Sinnott, 1990). Glucuronidation may affect binding of
phenolics to specific cellular targets, as in the case of resveratrol, but overall this
biotransformation does not seem to affect resveratrol’s in vitro antioxidant potential (Lu
et al., 2013). Additionally, in vitro models show that glucuronidation does not affect
quercetin’s estrogenic activity (Ruotolo et al., 2014). Though this metabolite in certain
cases does not seem to have diminished bioactivity compared to the parent compound,
the increase in its water solubility increases its potential for excretion and thus may
impact bioactivity by limiting the half-life and concentrations in target tissues.
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Figure 3. Summary of Phase II metabolism. Phase II metabolism of the flavan-3-ol (-)epicatechin (EC) can produce metabolites that differ in bioactivity due to a change in
chemical reactivity and hydrophobicity compared to the parent compound. Conjugation
can occur at other and additional R-OH positions than those as displayed in the figure.
Abbreviations: UGT: UDP-glucuronyltransferase; COMT: catechol-O-methyltransferase;
SULT: sulfotransferase.

1.5

Transport of Phenolic Compounds

After phenolics are conjugated by the Phase II metabolizing system, they can be
transported to excretory pathways or systemic circulation leading to exposure to target
tissues. Efflux can occur at various sites along the gut, liver, and kidney by transporters
such as permeability glycoprotein (P-gp), also called multidrug resistant protein 1 (MDR1)
(Walle, 2004). P-gp has a net effect of lowering apparent oral bioavailability of
flavonoids, such as epicatechin-3-gallate (ECG), by promoting efflux from the enterocyte
to the intestinal lumen (Vaidyanathan and Walle, 2003). However, phenolic interactions
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with transporters may be competitive, and certain phenolic compounds that have a
higher affinity for these MDR transporters may serve to enhance absorption of others.
For example, gallated catechins have been shown to enhance bioavailability of other
phenolic compounds in tea (Tagashira et al., 2012), which may be related to their ability
to inhibit P-gp by binding to its active site (Qian et al., 2005). It is therefore important to
consider phenolics in the context of a whole-food system containing various types of
phenolics and other compounds, such as tea, which may lead to an overall increased
absorption of targeted phenolics in the same system compared to isolated compounds.
There is an important distinction to make in regard to efflux transporters, as they
can either increase or impair delivery of phenolics to target tissues. In enterocytes,
MRP2 localizes to the luminal side (Leslie et al., 2001), MRP3 to the serosal position,
while MRP1 can be located on both sides (Del Rio et al., 2013; Estudante et al., 2013).
Due to this polarization, MRP 1 or 2 can both facilitate efflux of compounds into
excretory pathways in contrast to MRP3, which can act to enhance transport of these
compounds to target tissues by increasing flux into the portal vein. Since the Phase II
and efflux systems may reduce the activity of phenolic compounds, they may be a
potential target to assess if affected in diseased conditions.

1.6

Metabolic Regulation of Xenobiotic Transport and Metabolism: Potential
Implications for Phenolics

Since xenobiotic transport and metabolism are dependent on normal metabolic
regulation, it can be expected that diseases such as obesity or diabetes may in fact alter
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these systems and by extension impact bioavailability and effectiveness of phenolics.
Several clinical trials that will be discussed have reported minimal to no improvements
in physiological markers among obese or diabetic subjects given phenolic-rich foods,
while there are improvements in groups without these conditions. It is therefore logical
to assume that phenolics may not be as effective in improving health outcomes if a
disease state such as obesity or diabetes is present. We will further review studies
demonstrating that high therapeutic doses of phenolics are often needed to elicit
changes in the health status of obese or diabetic individuals, further suggesting
alterations in the absorption and metabolism of these compounds that results in their
lowered effectiveness.

1.7

Clinical Trials Comparing Efficacy of Phenolic Compounds in Healthy vs. Obese or
Diabetic Populations
Several studies suggest differential effects of phenolic compounds in lean versus

obese or diabetic populations in regards to cardiovascular function. Banini et al. (Banini
et al., 2006) found that consumption of dietary grape phenolics produced a differential
response between diabetic and non-diabetic individuals on markers of cardiovascular
health and glucose control. To assess this difference, diabetic and healthy individuals
were given either 150 mL of juice, wine, or a dealcoholized wine beverages made from
Muscadine grapes for 28 days. Non-diabetic controls in this study had a BMI range from
about 27-30 kg/m2 (overweight), and the diabetic BMI range was from about 35-40
kg/m2 (obese). Comparing changes in lipid profiles, grape juice consumption significantly
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lowered triglyceride levels in only the non-diabetic participants. Diabetics consuming
the dealcoholized wine had decreased insulin levels at the end of the study compared to
baseline, however this reduction may simply have been from consuming less
carbohydrate and not necessarily due to phenolic treatment. One strength of this study
is that it tested standard wine along with dealcoholized wine, which is significant since
alcohol can be a potential confounding factor by effecting health outcomes and/or
bioavailability (Brien et al., 2011; Dragoni et al., 2006). While the authors did not report
a specific phenolic composition of the juice, an analysis elsewhere suggest that 150 mL
of the wine could contain approximately 443 mg total phenolics, including 6 mg of gallic
acid (Otaolaurruchi et al., 2007). While this was a lower dose compared to other studies
reviewed here, lipid profile still improved in the overweight, non-diabetic subjects, but
the diabetic group did not show these improvements.
Similarly, Davison et al. (Davison et al., 2008) found that higher doses of cocoa
phenolics are needed to produce a response in cardiovascular markers and glucose
control in overweight and obese individuals. Participants in this study had an average
baseline BMI of 33.5 kg/m2 and were given a cocoa beverage with either low or high
levels of flavan-3-ols (36 versus 902 mg per day). This treatment occurred over a period
of 12 weeks, with measurement tests conducted at baseline, 6, and 12 weeks.
Measurements at 12 weeks showed that only the high-dose group had an increase in
flow-mediated dilatation, a marker of cardiovascular function, along with improved
markers of insulin resistance. A strength of this study is the relatively prolonged
treatment time period, in conjunction with the low and high doses to demonstrate the
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point at which a physiological response takes effect. In this study, there was not a
normal weight group to directly compare the results and the relatively high dose of
phenolics (902 mg of flavan-3-ols) with more relevance to supplemental treatments
rather than dietary exposure. Though this study does not point specifically to an
underlying mechanism explaining why a much higher dose was required to elicit a
response compared to other studies, these data suggest that a higher dose of flavan-3ols is needed to be effective in promoting cardiovascular health and normal insulin
markers in overweight and obese individuals.
Almoosawi et al. (Almoosawi et al., 2012) reported that cocoa phenolics elicit a
differential response in cardiovascular and glucose markers in overweight and obese
individuals versus normal weight participants. In this study, normal weight (BMI 18.524.9 kg/m2) and overweight plus obese (BMI ≥ 25 kg/m2) participants were given 20 g of
a cocoa confection containing 500 mg total phenolics (19 mg from flavan-3-ols
epicatechin and catechin) daily for 4 weeks. The study used a crossover design, and the
control product consisted of participants receiving a sham cocoa confection with its
phenolics removed. The overweight/obese group had reductions in both systolic and
diastolic blood pressure in addition to blood glucose levels at the conclusion of the
study. The normal weight group only had a reduction in systolic blood pressure, but this
was likely due to the normal blood pressure and glucose levels among individuals in the
lean group. This study used a well-designed control confection that matched lipid
profiles while excluding phenolics. As cocoa butter fatty acids alone have been reported
to improve cardiovascular markers (Mursu et al., 2004), this suggests the direct
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difference in phenolic impacts. One reason for observing the positive results in both the
overweight and obese group is their categorization in the study. If the two groups were
separated in the study, statistical analysis may have shown overweight participants
responding to the treatment but not the obese. Though some research has not been
able to confirm a significant relationship between BMI and effective dose of polyphenols
(Almoosawi et al., 2010), the authors still found the results unexpected since they
conflict with some previous research suggesting lowered efficacy of polyphenol
treatment in obese populations. Although an effect was observed in this study on
markers of glucose control and cardiovascular health in the overweight and obese
population, it still leaves questions, including why studies show responders and nonresponders to phenolic treatments. This question may have been better answered if the
overweight and obese individuals were separated into their own groups, as only those
with BMI levels in the obese range may be negatively affected.
Combined, these studies suggest that phenolics may have differential effects in
lean versus obese or diabetic populations in regards to cardiovascular function.
However, it is not clear as to the underlying reasons for this difference. It is logical that
differences in absorption and metabolism of phenolics between healthy and obese or
diabetic individuals would be responsible in part for these observations. With lower
absorption, higher doses may be required to achieve appropriate circulating and tissue
concentrations to elicit a physiological response. While the studies described did not
directly measure absorption of phenolics, evidence from in vitro, animal, and other
clinical studies provide more insight on this potential effect.
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1.8

Pharmacokinetic Analyses in Animals Models Suggest Obesity and Diabetes Affect
Xenobiotic Transport and Metabolism
Several studies have suggested that obese or diabetic conditions may lead to a

fundamental alteration in phenolic xenobiotic metabolism and transport systems critical
for delivering the effect of this bioactive. Table 1 summarizes the pre-clinical animal
models showing that both obesity and diabetes affect the xenobiotic metabolizing and
transporting systems critical for delivery of phenolics (Lee et al., 2010). Many of these
studies sought to determine differences in individual pharmacokinetic parameters of
phenolics and other compounds in these diseased conditions relative to healthy models
to help elucidate underlying mechanisms for the varying physiological responses to
these compounds.
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Table 1. Summary of pre-clinical pharmacokinetic studies.
Study and
Model and Health Status
Reference
Liu, 2010 (64)

Male Sprague-Dawley
rats

Source
Baicalin, i.v.

CMAX
Dose
AUC
TMAX
Time Compound
-1
-1
-1
(mg∙kg ) (ng∙hr∙mL ) (ng∙mL ) (hr)
(hr)
10

Baicalin

12

STZ-induced diabetic rats
Male Sprague-Dawley
rats

Baicalin, oral

24

200

STZ-induced diabetic rats

Yu, 2010 (66)

Male Sprague-Dawley
rats

Coptidis
Rhizomea
extract

8 Jatrorrhizine

34

Male Wistar rats

Mangiferin

∞

Male Sprague-Dawley
rats

18,000

−

−

1,500

−

11,200

−

−

930

−

48,500

3,390;
0.2; 8.4
3,860

240

17; 19

100,800

5,740;
0.2; 8.8
8,630

500

29; 43

2.88

8.5

4.4

2,150

1,050

1.88

63.2

30.9

3,820

720

0.73

9.6

1.8

8,950

2,000

2.25

22.4

5.0

6,400

−

−

320

−

Metabolite 1

13,100

223

3 min

655

11.2

Metabolite 2

12,300

410

3 min

615

20.5

Liquiritigenin

5,910

−

−

296

−

Mangiferin

400

12 Liquiritigenin

20

-1
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STZ-induced diabetic rats

Liquiritigenin,
i.v.

-1

150

STZ-induced diabetic rats
Kang, 2010
(86)

(ng∙mL ∙mg )

290

STZ-induced diabetic
rats
Liu, 2012 (75)

CMAX/dose

AUC/dose
-1
-1
(ng∙hr∙mL ∙mg )
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Table 1, con’d. Summary of pre-clinical pharmacokinetic studies.
Study and
Reference

Model and Health
Status

Male SpragueDawley rats

Source

Time
(hr)

Liquiritigenin,
oral

Male Donryu rats
STZ-induced
diabetic rats

Morphine

∞

Dose
AUC
-1
-1
(mg∙kg ) (ng∙hr∙mL )

CMAX
(ng∙mL )

TMAX
(hr)

-1

CMAX/dose
AUC/dose
-1
-1
(ng∙hr∙mL ∙mg ) (ng∙mL-1∙mg-1)

Metabolite 1

15,400

322

3 min

770

16.1

Metabolite 2

19,300

643

3 min

965

32.2

297

26.0

7 min

5.94

0.52

Metabolite 1

34,833

132.8

15 min

697

2.7

Metabolite 2

32,000

246.7

15 min

640

4.9

Liquiritigenin

443

49.7

5 min

8.86

1.0

Metabolite 1

32,333

298

15 min

647

6.0

Metabolite 2

33,000

558

15 min

660

11.2

12,200

−

−

813

−

7,000

−

−

466

−

Liquiritigenin

STZ-induced
diabetic rats

Hasegawa,
2010 (76)

Compound

Morphine

50

15

20
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The flavone glycoside baicalin, found in the Chinese herb Scutellaria baicalensis,
was reported to be excreted at faster rates in diabetic compared to healthy rats (Liu et
al., 2009). Though diabetic rats had significantly higher plasma AUC of the compound
when provided a 200 mg/kg baicalin i.g. dose (48.48 vs. 100.77 μg∙hr∙mL-1; normal vs.
diabetic), the normal group had significantly higher levels of the compound when given
a 12 mg/kg dose by i.v. (18.02 vs. 11.20 μg∙hr∙mL-1; normal vs. diabetic). Since baicalin is
transported across the ileum after the glucuronide moiety is cleaved, both groups of
rats were tested for activity of β-glucuronidase, the enzyme that catalyzes the cleavage.
There was a 1.7-fold increase in activity of this enzyme in the duodenum of the diabetic
animals, demonstrating a mechanism for the observed apparent increased
bioavailability via the oral dose. Still unanswered in this study is the underlying
explanation for increased systemic clearance that drives the decreased baicalin plasma
concentrations in the diabetic rats compared to the normal animals when given the i.v.
dose.
Cao et al. (Cao et al., 2012) reported that plasma clearance and/or decreased
absorption of salicylic acid was altered in Goto-Kakizaki (GK) diabetic rats, a model for a
non-obese diabetic phenotype, as compared to normal Wistar rats. Salicylic acid was
administered in feed, and plasma samples were collected over the course of 15 weeks.
Concentration of salicylic acid in GK rat plasma was consistently significantly lower
compared to the Wistar rats over the course of the test period, which may be due to
increased apparent clearance in GK (94.6 mL∙h-1kg-1) compared to Wistar rats (68.0
mL∙h-1kg-1). Since this study administered the salicylic acid in their feed, it is also possible
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that there were alterations in digestion or intestinal transport that decreased
absorption of this compound. Still, the authors noted the clinical implications of the
lower salicylic acid plasma values in the diabetic rats by concluding that diabetics may
need increased dosage of compound to overcome increased excretion rates (Cao et al.,
2012).
Similar effects have been observed in non-phenolic compounds that rely on
similar transport and metabolizing pathways. Yu et al. (Yu et al., 2010) noted elevated
plasma clearance of the phenolic-like alkaloid jatrorrhizine in diabetic Sprague-Dawley
rats compared to healthy controls. In this study, a plant extract rich in jatrorrhizine was
administered by intestinal perfusion, and plasma from the portal vein was collected. The
results showed that the Cmax (maximum concentration) in diabetic animals was 9.5-fold
greater and the AUC was 7.5-fold greater than the non-diabetic control. Probing P-gp
function with Rho123 found it to be less active in the diabetic rats, and Western blot
confirmed that there was also decreased protein levels of P-gp in all segments of the
small intestine. The authors commented that compared to the normal group, there was
a greater increase in the portal vein concentration of jatrorrhizine in the diabetic
animals, but not a corresponding higher amount of compound in the peripheral plasma.
This first appears to be a paradox since the compound must be transported to another
compartment after going through the portal vein, but they seem to support the data
from Liu et al. suggesting increased clearance from systemic circulation to urine in
diabetic animals due to greater transport of jatrorrhizine across the small intestine but
lower levels in the periphery.
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1.9

Human Clinical Trials suggest Obesity and Diabetes affect Xenobiotic Transport
and Metabolism
Since bioactivity of phenolics is largely dependent upon their metabolism by key

Phase II enzymes (Silberberg et al., 2006), it is necessary to consider the systems that
may be altered in diseased conditions. Early research documented fundamental
differences in the xenobiotic transport and metabolizing systems in obese or diabetic
individuals (Gwilt et al., 1991). While many studies in this area have focused on
pharmaceuticals, interestingly, the effect of disease states on these systems has also
been investigated using phenolic compounds. As both phenolics and many
pharmaceuticals target the Phase II and III metabolizing systems, research utilizing
pharmaceuticals is also included in this discussion.
For instance, Abernethy et al. demonstrated the potential influence of obesity on
xenobiotic metabolizing systems (Abernethy et al., 1983). In this study, normal weight
and obese subjects were given a 30 mg oral dose of the benzodiazepine oxazepam,
excreted after glucuronidation, and it was found that plasma clearance of oxazepam
increased significantly in the obese (157 mL/min) compared to the normal weight group
(50 mL/min). Although doses for many pharmaceutical treatments reflect changes in
dose based on weight, it is possible that obesity can fundamentally increase levels or
activity of Phase II metabolizing enzymes (Brill et al., 2012). This elevated metabolism
can result in an increase in the rate at which phenolic compounds are metabolized and
excreted and may, in turn, decrease the potential for effective biological activity.
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In addition, clinical studies show that pharmacokinetic parameters of the
stilbenoid trans-resveratrol differ depending on health status of the population
(summarized in Table 2). Boocock et al. (Boocock et al., 2007) administered 1,000 mg of
trans-resveratrol to healthy, non-obese participants and observed an AUC of 544.8
ng∙hr∙mL-1 and Cmax of 117 ng/mL, but when 1,500 mg of trans-resveratrol was
administered to an overweight/obese (mean BMI = 31.8) population with hepatic
steatosis, it resulted in an AUC of 705 ng∙hr∙mL-1 and a Cmax of 65.7 ng/mL (Chachay et al.,
2014). These studies can be more easily compared when normalizing these parameters
by dose, which reveals that the healthy participants in Boocock et al. had an
approximately 15% greater AUC/dose and a more striking 167% greater transresveratrol Cmax/dose compared to the overweight/obese population in Chachay et al.,
demonstrating a potentially reduced ability to achieve a threshold for therapeutic
concentrations. As non-alcoholic hepatic steatosis has been reported to be present in
approximately 66% of obese (Sabir et al., 2001) and even 18% of lean populations
(Younossi et al., 2012), early stages of this condition may be playing a role in liver
function. Thus, proper liver function may potentially be affecting phenolic metabolism in
certain studies given prevalence of hepatic steatosis in the population.
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Table 2. Comparison of clinical pharmacokinetic studies using resveratrol in overweight/obese and normal weight populations.
Study and
Reference

CMAX
Dose
AUC
-1
-1
(mg∙kg ) (ng∙hr∙mL ) (ng∙mL-1)

CMAX/dose
TMAX
AUC/dose
-1
-1
(hr) (ng∙hr∙mL ∙mg ) (ng∙mL-1∙mg-1)

Time
(hr)

Compound

Overweight/obese
Chachay,
(mean BMI = 31.8) trans-resveratrol
2014 (72) humans with hepatic
capsule
steatosis

6

trans-resveratrol
(no metabolites
measured)

1,500

705

65.7

1

0.47

0.0438

Boocock,
2007 (71)
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trans-resveratrol

1,000

544.8

117

0.76

0.54

0.117

Glucuronide 1

3,059

473.6

2.25

3.06

0.475

Glucuronide 2

2,589

672.6

1.75

2.59

0.673

Sulfate

10,053

2,102

2

10.1

2.10

Resveratrol +
metabolites

16,246

3,365

−

16.3

3.37

Health Status

Healthy humans

Source

trans-resveratrol
capsule
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1.10 Pre-clinical and In Vitro Data Suggest Obesity and Diabetes Affect the Phase II and
III Metabolizing Systems
The observed alterations in xenobiotic metabolism in obese and diabetic humans
coincide with animal research done by Liu et al. (Liu et al., 2012) and additional studies
which show differential expression of key Phase II metabolizing enzymes according to
health status (see Table 3).When male Wistar diabetic rats were orally given 400 mg/kg
of the xanthone mangiferin (a C-glycoside found in plants in the Anacardiaceae family),
plasma AUC was significantly greater in the diabetic rat group (3,817.5 vs. 8,953.4
ng∙hr∙mL-1; healthy vs. diabetic). Although PK parameters of metabolites were not
determined, liver mRNA expression of select Ugt1a family enzymes increased 2.28-3.93fold, Ugt2b8 increased 4.39-fold, and Sult1a1 increased 1.62-fold in diabetic rats. In
contrast, the liver mRNA expression of Comt decreased 1.72-fold, Ugt2b-family enzymes
decreased by approximately 2-fold, and there was a 6.67-fold reduction in Sult1c1.
Overall, these data indicate that differences in pharmacokinetic parameters in the
diabetic state may be due to fundamental alterations in metabolizing systems.
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Table 3. Summary of pre-clinical molecular-based studies.
Study and Reference

Model and Health Status

Tissue Type

Xenobiotic, Transport, and
Metabolizing System

Direction of Change

Wang, 2002 (76)

Male Wistar STZ-induced diabetic rats

Liver

COMT activity

↓

Braun, 1998 (85)

Male B/Wor diabetic rats

Liver

Ugt1a1
mRNA; protein; activity

↑

Burant, 1994 (105)

Male Sprague-Dawley STZ-induced diabetic rats

Enterocytes

Glut2, Glut5, Sglt1
mRNA and protein

↑

Maeng, 2007 (111)

Male Sprague-Dawley STZ-induced diabetic rats

Brain

P-gp protein

↑

Zhang, 2011 (89)

Male Sprague-Dawley STZ-induced diabetic rats

Liver

Abcb1a, Abcb1b
mRNA; protein (P-gp)
Abcb1a, Abcb1b
mRNA and protein (P-gp)
Abcb1a mRNA; Abcb1b mRNA;
protein (P-gp)

↓ / no change

Intestinal mucosa
Kidney

↓
↑ / no change / ↑

Liu, 2006 and 2007
(91,92)

Male Sprague-Dawley and
ICR STZ-induced diabetic rats

Brain cortex

P-gp protein

↓

Nawa, 2010 (90)

Male ddY STZ-induced diabetic mice

Ileum

P-gp protein

↓

van Waarde, 2002 (93)

Male Wistar STZ-induced diabetic rats

Liver

Mdr2
mRNA and protein
Mrp2
mRNA; protein
Mct1
mRNA and protein

↑
No change / ↓

P-gp protein

↓

Liver
Nikooie, 2013 (94)

Male Wistar STZ-induced diabetic rats

Soleus muscle

Yu, 2010 (66)

Male Sprague-Dawley STZ-induced diabetic rats

Small intestine

↓
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Table 3, con’d. Summary of pre-clinical molecular-based studies.
Study and Reference

Model and Health Status

Tissue Type

Liu, 2012 (75)

Male Wistar STZ-induced
diabetic rats

Duodenum and jejunum
Ileum
Liver
Liver
Liver

Kang, 2010 (86)

Hasegawa, 2010 (83)

Kim, 2004 (87)

Male Sprague-Dawley STZinduced diabetic rats

Male Donryu STZ-induced
diabetic rats

Male Sprague-Dawley vs.
obese Zucker rats

Xenobiotic, Transport, and
Metabolizing System

Direction of Change

Mdr1a and Mdr1b (P-gp)
mRNA
Mdr1a and Mdr1b (P-gp)
mRNA

↓

Comt mRNA

↓

Ugt1a3, Ugt1a7, Ugt2b3, Ugt2b6,
Ugt2b12
mRNA
Ugt2b3 and Ugt2b8
mRNA

↑

↑
↓

Liver

Sult1b1 mRNA

↓

Liver

UDP-glucuronic acid

↑

Intestine

UDP-glucuronic acid

no change

Glucuronidation probed using
morphine

UGT

↑

Liver

Ugt2b1 mRNA

↑

Liver

Mrp2 mRNA; Mrp3 mRNA

↓/↑

Liver

Ugt1a1, Ugt1a6, Ugt2b1, Mrp2, Oatp2
mRNA

↓
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Table 3, con’d. Summary of pre-clinical molecular-based studies.
Study and Reference

Xu, 2012 (84)

Model and Health Status

Male obese C57BL/6J Lep

ob/ob

mice

Tissue Type

Xenobiotic, Transport, and
Metabolizing System

Direction of Change

Liver

Ugt1a1, Ugt1a6, Ugt1a9, Ugt2a3,
Ugt3a1, Ugt3a2
mRNA

↑

Liver

Ugt2b1 mRNA

↓

Lucas-Teixeira, 2002 (77)

Obese Zucker rats

Jejunal mucosa

COMT activity

↑

Koide, 2011 (78)

Male C57BL/6J diet-induced obese rats

Liver

Total UGT activity

↑

Liver

SULT2A1 protein and activity

↓

Kim, 2004 (87)

Female C57BL/6 mice treated with LPS

Liver

Sult2a1 mRNA and total SULT activity

↓

Shimada, 1999 (81)

Male Sprague-Dawley rats treated with LPS

Liver

Total SULT activity

↓

Ho, 2007 (113)

Male Sprague-Dawley rats treated with LPS

Liver

Mdr1b mRNA

↑
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Further, Wang et al. reported that COMT methylation activity measured over 30
min decreased by 28.1% in the liver of male Wistar rats with uncontrolled diabetes, but
the enzyme's function was rescued by restoring blood glucose levels to a normal range
(Wang et al., 2002). This suggests that the downstream effects from chronic elevated
blood glucose may contribute to alterations in methylation activity. In contrast, COMT
Vmax increased by 80.5% in obese Zucker rats in the jejunum compared to lean rats
(Lucas-Teixeira et al., 2002). Thus, changes in COMT activity and expression appear to be
dependent on tissue type and homeostatic aberrations, such as elevated blood glucose
levels associated with diabetes.
Protein levels of SULT enzymes, along with their activity, have also been reported
to be affected by obesity, diabetes, and associated comorbidities. For instance, male
C57BL/6J mice with diet-induced obesity have decreased protein levels of SULT2A1 in
liver (Koide et al., 2011). Additionally, research on human clinical samples has shown
similar trends (see summary in Table 4). Both SULT1C4 mRNA and protein expression
has been reported to increase in humans with fatty liver, a common comorbidity of
obesity (Hardwick et al., 2013), however liver SULT1A1 protein levels are significantly
lower in individuals with either liver steatosis or diabetes (Yalcin et al., 2013). Thus, it
appears that specific isoforms are differentially impacted through pathways mediated
by inflammatory signaling associated with obesity and diabetes. For example, liver Sult
isoforms 1a1, 1b1, and 1c1 mRNA expression and their respective proteins decreased in
male rats after administering the inflammatory agent bacterial lipopolysaccharide (LPS)
(Shimada et al., 1999). However, there was no reduction in Sult mRNA expression in rats
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pretreated with the anti-inflammatory compound dexamethasone, which coinsides with
results from another study in female C57BL/6J mice that showed a decrease in SULT
activity under inflammatory conditions (Kim et al., 2004a). As such, both obesity and
diabetes, as well as related inflammatory stress from these conditions appear to have a
role in ultimate status of SULT enzymes and their activities.
Data from animal and human studies provide conflicting information on the
impact of obesity and/or diabetes on glucuronidation processes. Male diabetic Donryu
rats had approximately twice the circulating concentration of morphine-3-glucuronide
from 185-365 min after an initial 15 mg/kg morphine IV dose compared to normal
controls (Hasegawa et al., 2010). Additionally, Xu et al. (Xu et al., 2012) found that
obese Lepob/ob compared to normal C57BL/6J mice had significantly increased
acetaminophen glucuronidation velocity in hepatocytes (0.15 vs. 0.23 nmol∙min-1mg1

∙protein), which correlated to an approximately 5-fold increase in hepatocyte mRNA

expression of Ugt1a1 and Ugt3a1 isoforms in the obese mice. Comparing male diabetic
BB/Wor to normal Wistar rats showed that UGT1A1 enzyme activity increased from
0.231 to 1.816 nmol∙min-1∙mg-1 protein in permeabilized liver microsomes (Braun et al.,
1998). In streptozocin-induced diabetic male Sprague-Dawley rats, plasma AUC licoricederived flavanone metabolite liquiritigenin-7-O-glucuronide increased from 738 to 1,160
μg∙min∙mL-1 and Cmax from 24.6 to 38.6 μg/mL compared to normal controls (Kang et al.,
2010). In contrast, obese Zucker rats have a statistically significant 33-63% decrease in
the hepatic mRNA expression of the Ugt isoforms1a1, 1a6, and 2b1 compared to lean
Sprague-Dawley rats (Kim et al., 2004b). In humans, the diabetic condition has been
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reported to decrease both glucuronide enzyme activity and mRNA expression of the
UGT2B7 isoform of the enzyme by approximately 50% (Dostalek et al., 2011). However,
obese individuals are reported to have increased concentrations of oxazepam
glucuronide metabolites (Abernethy et al., 1983), and mRNA expression of UGT1A9 and
2B10 isoforms has been shown to be significantly higher in humans with non-alcoholic
fatty liver disease (Hardwick et al., 2013). While data overall are somewhat mixed,
evidence does support alteration in glucuronidation processes due to the obese or
diabetic state. Since these changes in glucuronidation can affect overall metabolite
profiles, excretion of phenolic compounds, and by extension apparent Cmax values, they
may potentially impact reaching threshold concentrations to elicit a physiological
response.
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Table 4. Summary of human molecular-based studies.
Study and Reference

Population and Health Status

Tissue Type

Xenobiotic, Transport, and
Metabolizing System

Direction of Change

Hardwick, 2013 (79)

Non-alcoholic fatty liver disease

Liver

UGT1A9 and 2B10
mRNA; protein; total UGT activity

↑ / no change / no change

SULTA1C4
mRNA; protein; total SULT activity

↑/↑/↓

Liver

SULT1A1
mRNA; protein; activity

no change / ↓ / ↓

Liver

SULT1A3
mRNA; protein; activity

no change / ↑ / ↓

Metz, 2008 (97)

Male and female,
lean (mean BMI = 22.6) vs. obese
(mean BMI = 35.3)

Leg skeletal
muscle

MCT1 protein

no change

Dostalek, 2011 (88)

Male and female diabetics

Liver

UGT1A9, UGT1A1, and UGT2B7
mRNA

↓

Kidney

UGT1A9, UGT1A1, and UGT2B7
mRNA

↓

Liver

SULT1A1
mRNA; protein; activity

no change / ↓ / ↓

Liver

SULT1A3
mRNA; protein; activity

no change / no change / ↓

Yalcin, 2013 (80)

Yalcin, 2013 (80)

Liver steatosis

Diabetics

Juel, 2004 (96)

Male Type II Diabetics

Leg skeletal
muscle

MCT1 protein

↓

Kim, 2004 (87)

Hep 3B cells treated with TNF-α and IL1

Hepatocytes

SULT2A1 mRNA

↓
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Disease state may also impact the Phase III metabolizing system by affecting P-gp
function and expression levels. Comparing 8-week old male Sprague-Dawley rats to
diabetic rats treated with insulin shows significantly greater Rho123 concentrations in
the liver (69.4 vs. 120.9 ng/g; normal vs. diabetic), intestinal mucosa (101,135 vs.
210,123 ng/g; normal vs. diabetic), and kidney (422.5 vs. 578.0 ng/g; normal vs. diabetic)
of diabetic rats demonstrating impaired P-gp function (Zhang et al., 2011). In ileal tissue
of diabetic male ddY mice, P-gp protein levels were 60% that of the control (Nawa et al.,
2010). Decreased P-gp function has also been demonstrated in the brain of diabetic
male Sprague-Dawley rats by showing that the ratio of brain tissue concentration to
plasma level of the P-gp substrate VCR is significantly greater in the diabetic group as
compared to the control (0.023 vs 0.072 mL/brain; normal vs. diabetic) (Liu et al., 2006).
This has been confirmed in male diabetic ICR mice, with brain concentrations of Rho
significantly greater in diabetic rats (13.69 ng/g) compared to normal controls (10.24
ng/g) (Liu et al., 2007). In contrast, van Waarde et al. (van Waarde et al., 2002)
interestingly found that the liver of diabetic Wistar rats had a 530% increase in protein
expression of MDR2 and a corresponding elevation in bile salt secretion compared to
control.
Though efflux transporters have an important role in the excretion of phenolics,
expression of transporters that drive transport of phenolics into the enterocyte and
other cells may also be altered in obesity and diabetes. In diabetic male Wistar rats,
Mct1 mRNA expression in soleus muscle is significantly lower than control (Nikooie et al.,
2013), in addition to decreased expression of MCT1 protein in the plantaris muscle
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(Enoki et al., 2003). Though this pattern has also been reported in male diabetic patients
with decreased skeletal muscle expression of MCT1 (Juel et al., 2004), obese individuals
did not show differences in muscle MCT1 protein levels compared to control (Metz et al.,
2008). Though MCT1 in human hepatic or intestinal tissue was not directly measured in
these studies, these may similarly be affected in diseased conditions.

1.11 Additional Potential Factors from the Obese and Diabetic Condition May Affect
Phenolic Pharmacokinetics
Although this review focused on critical xenobiotic metabolizing and transport
systems altered by obesity and diabetes, there are additional factors to consider that
may influence phenolic pharmacokinetic parameters in these conditions. One such
example is that there is an increase in glomerular filtration rate from the diabetic
condition (Premaratne et al., 2015), which could decrease plasma phenolic
concentrations by increasing their elimination through urine. In addition, kidney disease
that may result from late-stage diabetes can alter factors that influence xenobiotic
metabolism (Nolin et al., 2008).
Differences in the gut function between diabetic and normal rats may also
partially explain differential absorption of pharmaceutical compounds. Ogata et al.
(Ogata et al., 1997) compared absorption of the peptide cyclosporin A between GK and
Wistar rats by administering the compound orally or by i.v. When 10 mg/kg cyclosporin
A was given by i.v., the diabetic and normal group had similar plasma AUC of the
compound (21.9 vs. 20.6 μg∙hr∙mL-1; normal vs. diabetic), but when orally administered,
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the diabetic rats had significantly lower plasma AUC concentrations (11.3 vs. 1.8
μg∙hr∙mL-1; normal vs. diabetic). Since this compound is absorbed in the small intestine,
gastric emptying was determined using radiolabeled sodium chromate. While 90% of
the marker could be recovered in the distal section of the ilium of the normal group
after 2 h, only 60% could be recovered in the diabetic rats with 25% of the marker still
remaining in the stomach. It is important to point out that while this study compared
only two different breeds of rats, these results may be applicable in a broader sense to
the absorption of phenolic compounds because gut transit time can impact PK
parameters.
Another possible factor to consider is that of intestinal microbiota since
microbiota profiles can change under diabetic or obese conditions (Forslund et al., 2015;
Ley et al., 2005). As phenolics have low first-pass bioavailability, they reach the lower
gut where they may be catabolized into low-molecular weight compounds that are
potentially absorbed and then enter systemic circulation where they can exert biological
activity (Del Rio et al., 2013). Due to beneficial effects of phenolics potentially being
mediated by gut microbiota, disease states that perturb microbiota composition may
alter their efficacy (Tomás-Barberán et al., 2014). For example, Selma et al. (Selma et al.,
2015) found that production of bioactive catabolites of ellagic acid (urolithins) differ
between overweight/obese and normal weight individuals, decreasing potential efficacy
derived from these compounds.
In the diabetic condition, there are alterations to intestinal tissues that occur due
to elevated blood glucose levels, which may also affect phenolic transport. These
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changes may emerge because expression of the small intestinal carbohydrate
transporters SGLT1 and GLUT2 increase in diabetic rats, though controlling blood
glucose with proper insulin treatment restores them to normal levels (Burant et al.,
1994). This alteration can then potentially increase uptake of certain phenolics whose
transport is associated with glucose transporters.

1.12 Potential Underlying Mechanism for Altered Xenobiotic Metabolizing and
Transporting Systems in Obese and Diabetic Populations
A potential underlying mechanism for the differences in xenobiotic transport and
metabolism observed in obese and diabetic populations involves chronic, low-grade
inflammatory response prevalent in these conditions (Donath and Shoelson, 2011; Neels
and Olefsky, 2006). In a study mentioned previously, administering LPS to SpragueDawley rats resulted in a 36.8% reduction in hepatic sulfonation activity (Shimada et al.,
1999), which aligns with another report that LPS-induced secretion of inflammatory
cytokines and stimulation of the inflammatory processes alters drug metabolism
(Waring et al., 2013). Similarly, elevated insulin levels from diabetes may also induce
alterations that affect Phase II enzymes (Kim and Novak, 2007). In addition, Thibault et
al. (Thibault et al., 2007) reported that individuals with inflammatory bowel disease
have decreased expression of the MCT1 transporter, which was replicated in a
mechanistic in vitro study demonstrating that treating the intestinal cell line HT-29 with
the inflammatory cytokines IFN-γ and TNF-α dose dependably decreases mRNA
expression and protein levels of this transporter. The authors of the study hypothesize
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that the mechanism underlying this phenomenon may be due to an inflammatory
response element in the promoter region of the MCT1 gene. Hence, inflammatory
processes mediated though NF-κB signaling or another inflammatory signaling pathway
likely play a role in expression of MCT1 and by extension may impact absorption of
certain phenolics.
Further, the inflammatory response mediated through NF-κB induction is known
to modulate the expression of P-gp (Maeng et al., 2007). A review on P-gp expression in
the intestine suggests that it is increased in diabetic humans due to elevated
inflammatory cytokines and blood glucose (Kobori et al., 2013). In addition, the
transporter MRP3 responds to inflammatory stimuli, and has been shown to become
either up or downregulated depending on the animal model used in the study (Ho and
Piquette-Miller, 2007). More research is needed in humans to provide a definitive
answer on how disease states affect these transporters, however existing data do
suggest that the diabetic condition likely increases efflux transporter activity that could
then potentially increase excretion of phenolics.
Additional evidence supports the relationship between increased inflammatory
status and altered xenobiotic metabolizing and transporting systems. Individuals with
Crohn’s disease, a condition of elevated inflammation in the gut, have increased
expression of P-gp in intestinal and hepatic tissue (Fakhoury et al., 2006) and increased
permeability of tight junctions, making the gut less effective in maintaining barrier
ability (Al-Sadi et al., 2008). In addition, the elevation of protein kinase C in the diabetic
state leads to an increase in the p65 subunit of the NF-κB transcription factor, which
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then, in turn, increases P-gp levels in the liver (Kameyama et al., 2008; Maeng et al.,
2007). Also, MRP2/3 have both been found to be altered by increased inflammatory
status (Ho and Piquette-Miller, 2007; Le Vee et al., 2009). Figure 4 synthesizes this
information in a potential model to explain the altered absorption of phenolic
compounds apparent in those with increased inflammatory status due to obesity and
diabetes.

Figure 4. Potential mechanism for altered xenobiotic transport and metabolizing
systems in human (A) intestinal and (B) hepatic tissues. Increased NF-κB mediated
inflammation resulting from the diabetic and obese condition are believed to be
involved in the alterations. Dashed lines indicate potentially affected by increased NF-κB
signaling, and solid line indicates negatively affected.
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1.13 CONCLUSIONS & IMPLICATIONS
Absorption, metabolism, and transport of phenolic compounds to target tissues
are all essential for effective delivery of their bioactivity from food and dietary
supplements, and these processes appear to be affected by disease states such as
obesity or diabetes. The overall effect from these diseases is that they may create a
situation where application of phenolic-rich foods or supplements may not be as
effective as expected due to impairment of absorption and metabolism of phenolic
compounds and increased excretion. Subsequently, formulations and therapies may
have to be adjusted in order to accommodate for altered production of phenolic
metabolites into circulation and target tissues. While some evidence does exist for the
possible sources of the differences, it is critical to fully understand the underlying
mechanism for the observed differences in phenolic effectiveness and/or bioavailability
and metabolism between healthy and obese/diabetic individuals. Only then will
strategies to enhance effectiveness of preventative ameliorative therapies utilizing
these phenolic can be improved.
Continued research on the fundamentals of the absorption and metabolism of
phenolic compounds can help inform future studies utilizing phenolics in individuals
with obesity or diabetes. One goal of future research should be to specifically compare
the differential absorption of phenolic compounds in diseased versus healthy individuals.
Study design will have to be carefully addressed in order to elucidate the mechanism for
decreased absorption of phenolic compounds in those with obesity or diabetes.
Including administration of phenolic compounds by i.v. would allow for assessment of
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clearance from plasma and oral administration can assess absorption across the gut
epithelium. Experiments of this nature are needed to confirm differences in phenolic
absorption parameters between normal and diseased individuals. With evolving
research that targets the fundamentals of phenolic absorption comparing healthy and
diseased populations, researchers and product developers will be able to leverage these
findings to develop products and strategies that better target obese or diabetic
populations.
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CHAPTER 2.

CHARACTERIZATION AND QUALITATIVE ANALYSIS OF PLASMA-TARGETED
METABOLITES OF CATECHIN AND EPICATECHIN

As part of the manuscript “Synthesis and quantitative analysis of plasma-targeted
metabolites of catechin and epicatechin,” JW Blount1, BW Redan2, MG Ferruzzi2,3, BL
Reuhs3, BR Cooper4, JS Harwood5, V Shulaev1, G Pasinetti6, RA Dixon1, published in J.
Agric. Food Chem. 2015, 4;63(8):2233-40. 1Department of Biological Science, University
of North Texas, 2Department of Nutrition Science, Purdue University, 3Department of
Food Science, Purdue University, 4Bindley Bioscience Center, Purdue University, 5Purdue
University Interdepartmental NMR Facility, 6Department of Psychiatry, The Mount Sinai
School of Medicine
As this publication was a collaboration, the present chapter focuses on the
characterization and qualitative analysis of the metabolites since our collaborators
performed their synthesis.
Reprinted with permission from J. Agric. Food Chem., 2015, 63 (8), pp 2233–2240.
Copyright 2015 American Chemical Society

2.1

Introduction

Plant-derived polyphenolic compounds possess diverse biological activities,
including strong anti-tumor, anti-oxidant, anti-inflammatory, and anti-microbial
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activities (Dixon, 2001; Guo et al., 2009; Ishikawa et al., 1997). Previous work from our
laboratories has shown that polyphenolic compounds from multiple sources, including a
specific grape seed polyphenolic extract (GSPE), are capable of improving cognitive
functions and reducing brain neuropathology in animal models of Alzheimer’s Disease
through multiple mechanisms (Wang et al., 2008, 2012). At least a part of this effect
may be mediated through interference with aggregation of β-amyloid peptides into
neurotoxic, soluble high-molecular weight species (Wang et al., 2008).
GSPE is a complex mixture of proanthocyanidins (PACs, both oligomeric and
polymeric) and their monomeric units consisting of the flavan-3-ols (+)-catechin (C) and
(-)-epicatechin (EC) (Sharma et al., 2011). The flavan-ol units are assembled into the
various types of oligomers and polymers through C4→C8 or C4→C6 interflavan bond
and the individual units in the polymer can also be substituted with gallic acid. The
monomeric units, rather than the oligomers or polymers, are bioavailable and are the
bioactive components in the GSPE (Wang et al., 2012). These bioactive components, in
the form of glucuronidated and/or methylated phase II metabolites, reach the brain at a
concentration of 300-400 nM after 10 days of repeated dosing (Wang et al., 2012).
While knowledge of all metabolites found in plasma may be of broader significance for
understanding the therapeutic effects of GSPE on a range of disease phenotypes,
mechanistic studies, require knowledge of the exact structures of metabolites that
accumulate in brain or other tissue. To initiate such studies, we implemented a semisynthetic approach to generate sufficient quantities of flavan-3-ol metabolites for
unequivocal identification. We demonstrated that recombinant human
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glucuronosyltransferases of the UGT1A and UGT2B families can efficiently glucuronidate
epicatechin or 3’-O-methyl epicatechin in vitro, suggesting a method for the semisynthesis of brain-targeted flavan-3-ol metabolites (Blount et al., 2012). Of twelve
enzymes tested, UGT1A9 was the most efficient, and this enabled us to generate 3’-Omethyl-epicatechin-5-O-glucuronide to 50% overall yield (Blount et al., 2012). In the
present study, we have extended the above approach, in combination with chemical
methylation of catechin and epicatechin with iodomethane, to generate authentic
standards of the catechin and epicatechin metabolites found in the plasma and brains of
rats treated with GSPE. The structures of the metabolites were rigorously identified, and
we present a robust, validated protocol for the measurement of the levels of these
compounds in animal fluids.

2.2

Materials and Methods

2.2.1 Solid Phase Extraction (SPE) of Catechin and Epicatechin Metabolites from
Rodent Plasma
Rodent plasma samples were obtained from a previous pharmacokinetic study
using GSPE (Wang et al., 2012) that received approval from the Animal Care and Use
Committee at Purdue University. Plasma aliquots from control animals (no GSPE) and
treated animals (with GSPE) that was collected at sacrifice were thawed from -80°C
storage and quickly pooled separately at Purdue University. These control and GSPE
plasma samples were then re-aliquoted into individual vials and re-frozen at -80 °C until
analysis. For target assessment purposes, typical plasma was diluted fivefold with blank
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plasma to produce low dose plasma. Blank, low, and normal plasma samples were then
used for analytical validation at Purdue University and a parallel set of samples was sent
to University of North Texas for cross-lab validation.
Samples of frozen plasma were thawed at room temperature, and 300 µL of
acidified saline (9g NaCl in 1000 mL 0.1% v/v formic acid/H2O) were added to 200 µL of
plasma with vortex mixing. A SPE cartridge, 30 mg Oasis HLB column (Waters Co, Milford,
MA), was activated by addition of 1 mL MeOH followed by 1 mL DI H2O, after which the
plasma/saline mixture was loaded. Loaded SPE column was first washed with 1 mL 1.5
M formic acid, followed by 1 mL 95:5 v/v H2O: MeOH, and the eluate discarded.
Metabolites were then eluted with 2 mL 0.1% v/v formic acid/MeOH. Following elution,
ethyl gallate (10 µL of 10 µM stock solution) was added to the eluates as the internal
standard prior to samples being dried under vacuum (<50 mm Hg) at 37°C. The residues
were re-suspended in 160 µL 0.1% v/v formic acid/H2O + 40 µL 0.1% v/v formic
acid/acetonitrile, sonicated for 10s, vortex mixed for 10s, then transferred to centrifuge
tubes, which were centrifuged at 18,000g for 5 min to remove any particulates. The
clear supernatants were carefully transferred to 300 µL HPLC vials for analysis.
The ability of this extraction method to account for potential matrix effects were
assessed by comparing response of individual metabolite standards in the presence or
absence of blank plasma extracted matrix. Briefly, standards of catechin and its major
metabolites in GSPE rodent plasma at 50, 100, and 500 nM were resuspended either in
pure solvent (160µL 0.1% v/v formic acid/H2O + 40 µL 0.1% v/v formic acid/acetonitrile Standard) or in resolubilized blank plasma extracted by SPE (Standard + Matrix). By
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comparison of response between standards injected with or without plasma matrix an
estimate of matrix effects was established by using the following equation: % matrix
effect (% ME) = (peak area of standard with matrix – peak area of pure standard)/(peak
area of pure standard) x 100% (Ćirić et al., 2012).

2.2.2 LC/MS Analysis of C/EC Metabolites Extracted from Rodent Plasma
2.2.2.1 LC-TOF-MS for unknown metabolite characterization
Separation was achieved on an Agilent 1100 HPLC system using a Waters XBridge
BEH shield RP-C18 XP 2.1 x 100 mm 2.5 µm column following a 2 µm frit filter. The
column and autosampler were maintained at 40 °C and 10 °C, respectively. Mobile
phase A was 0.1% formic acid/H2O and B was 0.1% formic acid/ACN. A linear gradient
for elution was used at a constant flow rate of 0.26 mL/min. Initial conditions 5% B; 0-12
min: 5-15% B; 12-18min: hold at 15% B; 18-24 min: 15-40% B; 24-30 min: 40-50% B; 3031 min: 50-5% B; 31-36 min: hold at 5% B to reset gradient. Injection volume was set to
10 µL.
Mass spectra of flavan-3-ol metabolites were obtained using an Agilent 6200
time-of-flight (TOF) mass spectrometer in negative mode with a mass range of 100-1000
m/z, acquisition rate of 1.4 spectra/s and 714.3 ms/spectra. Source parameters were as
follows: gas temperature = 350 °C, drying gas = 9 L/min, nebulizer pressure = 35 psi,
capillary potential = 3500 V, fragmentor voltage = 145 V, skimmer voltage = 60 V, and
OCT 1 RF Vpp = 250 V.
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2.2.2.2 LC-MS/MS for metabolite quantification
Separation was achieved on an Agilent 1200 HPLC system as described in the
previous section, except for the gradient conditions as follows: initial conditions 10% B;
0-9 min: 10-35% B; 9-10 min: 35-65% B; 10-12 min: 65-10% B; 12-16 min: hold at 10% B
to reset gradient.
Analytes were quantified using tandem mass spectrometry (MS/MS) with an
Agilent 6460 triple quadrupole with electrospray ionization (ESI) in negative mode using
selected reaction monitoring (SRM) mass transitions. Acquisition SRMs were:
catechin/epicatechin, 289 → 245 m/z; catechin/epicatechin glucuronide, 465 → 289 m/z;
methyl catechin/epicatechin glucuronide, 479 → 303 m/z; ethyl gallate, 197 → 169 m/z.
All mass transitions used a dwell time of 200 ms and fragmentor voltage of 135 V.
Source parameters were as follows: gas temperature = 350 °C, gas flow = 11 L/min,
nebulizer pressure = 30 psi, sheath gas temperature = 350 °C, sheath gas flow = 11 L/min,
capillary potential = 3500 V, and nozzle voltage = 1000 V.
Intraday repeatability was assessed by extracting and analyzing pooled plasma n
= 5 times. Interday reproducibility was determined across n = 5 days using aliquot
pooled plasma. Repeatability and reproducibility were determined as relative coefficient
of variation (% CV) as calculated by (standard deviation/mean) x 100%. Limit of
detection (LOD) was defined as S/N = 3 and limit of quantification (LOQ) as S/N = 5. Both
values were obtained by producing serial dilutions of parent unmetabolized compounds
and metabolites. Data are presented as mean ± standard deviation. Signal to noise (S/N)
ratio was calculated using MassHunter software using the peak-to-peak method.
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2.3

Results and Discussion

2.3.1 Flavan-3-ol metabolites in rat plasma after feeding fractionated GSPE
There are multiple compounds derived from the flavan-3-ols catechin (2,3-trans)
and epicatechin (2,3-cis) found in mouse or rat plasma following the feeding of
monomer enriched grape seed extract (Wang et al. 2012). LC-MS analysis has indicated
that these compounds are glucuronides of (epi)catechin or methyl-(epi)-catechin. One
of the most abundant metabolites in plasma was previously identified by micro NMR as
3’-O-methyl-epicatechin-5-O-β-D-glucuronide (Figure 5), and we developed a semisynthetic route to this compound (Blount et al., 2012).
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Figure 5. Flavan-3-ol derivatives in rodent plasma. (A, B) Representative mass spectra of
flavan-3-ol metabolites in rodent plasma obtained on a LC/TOF system with a recording
range of 100-1000 m/z. The mass spectra of (A) is consistent with the mass of methylC/EC glucuronide, while (B) is consistent with C/EC glucuronide. (C) Structure of 2,3-cisflavan-3-ols. Epicatechin: R1 = R2 = R3 = OH; 3ʹ-O-methyl-epicatechin-5-O-β-Dglucuronide: R1 = glucuronic acid; R2 = OMe; R3 = OH.

2.3.2 Methylation of catechin and epicatechin
Our strategy for generation of standards of the other (epi)catechin metabolites
found in rat plasma was to: 1) synthesize methyl derivatives of catechin and epicatechin;
2) subject the (methylated) catechin and epicatechin to enzymatic glucuronidation; 3)
compare LC-MS mobility and fragmentation pattern of the synthetic compound to those
of the metabolites in plasma; 4) scale up the synthesis of compounds that match those
in plasma and confirm their structures by NMR.
Optimization of reaction conditions, as outlined in Materials and Methods,
resulted in maximum yields of 3ʹ-O-methyl-(epi)catechin of around 20%. The
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compounds corresponding to the 3ʹ- and 4ʹ-O-methyl isomers were purified by
chromatography using a Biotage Isolera system.

2.3.3 Glucuronidation of (methyl)catechin and epicatechin, and matching of synthetic
compounds to metabolites in plasma
Human recombinant glucuronosyltransferase UGT1A9, in the presence of UDPglucuronic acid, converts epicatechin to a number of products, the major one being the
3ʹ-O-glucuronide (a compound not found in the plasma of rats or mice fed GSPE), with
minor amounts of the 5-O-glucuronide (a minor metabolite in the plasma) (Blount et al.
2011). 3ʹ-O-methyl epicatechin is efficiently converted to 3’-O-methyl-epicatechin 5-Oglucuronide (a major plasma metabolite). The other compounds in plasma appear to be
derivatives of catechin. We therefore investigated conditions for the optimal
glucuronidation of methylated and non-methylated catechin by mammalian
glucuronosyltransferases and UDP-glucuronic acid. In contrast to epicatechin, we found
that pooled male mouse microsomes were more efficient at glucuronidation of catechin
and its derivatives than was UGT1A9, resulting in two major products from catechin
initially named CG14 and CG18 based on their approximate retention times by HPLC.
CG14 and CG18 were further purified by semi-preparative HPLC. Both compounds
possessed a molecular ion of 465, and matched peaks in the plasma of rats fed GSPE:
CG14 was a minor component, whereas CG18 was the second most abundant
metabolite.
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In a similar manner, glucuronidation of 3’-O-methyl catechin by mouse
microsomes in the presence of UDP-glucuronic acid led to the formation of multiple
products of which two, of retention time 19 and 24 minutes and molecular ions of 479
m/z (MCG19 and MCG24) matched metabolites in the rat plasma. Glucuronidation
products of 4ʹ-O-methyl-catechin did not match any of the compounds found in plasma.

2.3.4 Structural characterization of catechin and epicatechin metabolites
We have previously reported the structural characterization of 3’-O-methylepicatechin 5-O-glucuronide (Blount et al., 2012). In order to elucidate the structures of
CG14, CG18, MCG19 and MCG24, NMR spectroscopy was performed using a Bruker
Avance DRX 500 MHz spectrometer equipped with a cryoprobe. The metabolites were
dissolved in CD3OD (99.96% atom D; Sigma, St. Louis, MO) and then transferred to a 5
mm Shigemi tube (Wilmad Glass, Vineland, NJ). 2D NMR experiments using HSQC
(heteronuclear correlation spectroscopy), HMBC (heteronuclear multiple bond
correlation spectroscopy), and NOESY (nuclear Overhauser effect spectroscopy) were
performed. The spectral data (chemical shifts) for the four compounds are shown in
Table 5. The glucuronic acid moiety was assigned to the 7 position on (+)-catechin for
CG-14 and MCG-19 based on the presence of a HMBC cross peak between the anomeric
proton (H-1ʹʹ) and C-7. The assignment on CG-18 and MCG-24 was to the 5 position due
to a HMBC cross peak between H-1ʹʹ and C-5 (Supplemental Figure 3). The methyl group
was assigned to the 3ʹ position on MCG-19 and MCG-24 due to a NOESY cross peak
between H-2ʹ and the methoxy group, consistent with the synthesis of these compounds
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from 3ʹ-O-methyl catechin. Figure 6 summarizes the structures of the four catechin
metabolites, and its legend provides further description of how the positions of
methylation and glucuronidation were assigned.
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Table 5. NMR spectral data (chemical shifts) for CG14, CG18, MCG19 and MCG24.
CG-14
Position

Chem. Shift (ppm)
1

H

13

C

MCG-19
Position

Chem. Shift (ppm)
1

H

13

C

MCG-24
Position

Chem. Shift (ppm)
1

H

13

C

CG-18
Position

Chem. Shift (ppm)
1

H

13

C

2

4.59

82.55

2

4.63

82.54

2

4.62

83.04

2

4.59

82.53

3

3.97

68.17

3

4.01

68.29

3

4.13

66.49

3

4.05

66.31

4a

2.87

28.04

4a

2.90

30.88

4a

2.61

27.08

4a

3.00

28.35

4b

2.53

—

4b

2.54

—

4b

2.17

—

4b

2.60

—

6

6.25

96.94

6

6.22

96.94

6

6.34
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Figure 6. Structures assigned to CG14, CG18, MCG19 and MCG24. The glucuronic acid moiety was able to be assigned to the 7
position on (+)-catechin for CG-14 and MCG-19 based on the presence of a HMBC cross peak between the anomeric proton (H-1ʹʹ)
and C-7. The chemical shift of C-7 was determined by a HMBC cross peak between H-8 and C-7. Further support of this
connectivity was provided by the absence of a cross peak between H-1ʹʹ and C-5 (chemical shift determined by a cross peak
between H-4 and C-5). The assignment on CG-18 and MCG-24 was to the 5 position due to a HMBC cross peak between H-1ʹʹ and
C-5. The methyl group was assigned to the 3ʹ position on MCG-19 and MCG-24 due to a NOESY cross peak between H-2ʹ and the
methoxy group. HMBC: solid line; NOESY: dashed line
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Several studies have reported the presence of PA metabolites in blood plasma
after feeding animals with PA preparations or foods rich in PAs (Baba et al., 2000, 2001;
Feng, 2006; Piskula and Terao, 1998; Spencer et al., 2001). The metabolites were
partially identified as sulfonated, glucuronidated and/or methylated derivatives of
epicatechin and catechin (Abd El Mohsen et al., 2002; Baba et al., 2000; Piskula and
Terao, 1998; Spencer, 2003), with most studies focusing on the epicatechin derivatives.
Definitive structures, particularly with respect to the position of glucuronidation, were
not systematically assigned for many of the biologically relevant metabolites. The
present systematic approach to the synthesis and identification of predominant plasmaderived metabolites of flavan-3-ols present in plasma of rodents dosed with GSPE
provides a blueprint for the development of improved methods for the evaluation of
bioavailability of bioactive polyphenols, as well as a source of standard target molecules
for evaluating modes of action.

2.3.5 Cross-validated analytical method for determining plasma levels of catechin and
epicatechin metabolites
LC-MS/MS using an Agilent 6460 Triple Quadrupole system was selected as the
analytical method to determine the levels of catechin and epicatechin metabolites in
samples of plasma from rats fed GSPE, due in part to the sensitive and selective nature
of this method as well as the broad application of this method in the literature (Roura et
al., 2008; Tsang et al., 2005; Urpi-Sarda et al., 2009). Initially, the linear dynamic range
for each molecule (catechin, epicatechin, two catechin glucuronides, two methyl-

56
catechin glucuronides and one methyl-epicatechin glucuronide) was determined for
concentrations ranging over 4 orders of magnitude (pM-μM), with lowest
concentrations in the 250-650 pM range (see Figure 7 for representative
chromatograms). The linear dynamic range was observed to be excellent (Table 6) and
provides the ability to quantify these compounds across a range of concentration typical
in biological fluids and tissues. Metabolites were extracted from plasma by solid phase
extraction (extraction recovery was estimated to be 96.0 ± 3.1% based on internal
standard recovery) as described in Materials and Methods.
Measurement of effects of matrix and plasma concentration, and intraday and
interday variability revealed the method to be highly robust and efficient at limiting ion
suppression or other matrix effects commonly reported in analysis of biological
samples(Gardana et al., 2007; Li et al., 2007; Matuszewski et al., 2003), but rarely
accounted for. As expected, there was a greater matrix effect at lower concentrations.
The % ME when measuring catechin ranged from -7.84% at 500nM to -20.7% at 50nM.
MCG24 ranged from -13.5% at 500nM to -23.0 at 50nM. Finally, CG18 ranged from 13.1% at 500nM to -15.7% at 50nM. Since metabolites appear in rodent plasma at
approximately 300-400nM after repeated dosing of GSPE, using the SPE procedure
results in underestimating metabolites by about 13%.
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Table 6. Linear dynamic ranges for the quantitation of (methyl)catechin and (methyl)epicatechin glucuronides by LC-MS/MS.

(R )

LOQ (S/N=5)
MOC

LOD
(S/N=3)
MOC

y = 7E+09x+ 528.31

0.9997

138.9 pmol

55.5 pmol

5nM-50µM

y = 7E+09x+ 689.79

0.9997

106.4 pmol

48.4 pmol

3’OMe-EC-5-O-glucr

250pM-2.5µM

y=5E+11x– 3699.8

0.9998

2.05 fmol

1.07 fmol

CG18

500pM-10µM

y = 4E+11x+ 403.99

0.9999

10.6 fmol

3.41 fmol

CG14

500pM-10µM

y=6E+11x– 16601

0.9998

3.68 fmol

1.2 fmol

MCG19

650pM-10µM

y=2E+11x+ 12580

0.9990

5.80 fmol

2.80 fmol

MCG24

500pM-20µM

y=4E+11x– 31920

0.9994

4.70 fmol

1.03 fmol

Compound

Range

Regression line

C

5nM-50µM

EC

Linearity
2
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The Horowitz ratio (HorRat), a well-recognized normalized performance
parameter that provides a measure of laboratory precision, was calculated for
individualized metabolites based on the equation described by Horwitz and Albert
(Horwitz and Albert, 2006). HorRat values ranging from 0.13 to 1.29 indicated the high
reproducibility of this method. While lower values of the HorRat (0.13-0.21) do fall
outside of the generally accepted range, it is important to note that these were for
minor metabolites (C-7-O-glucuronide, 3’-O-Me-C-7-O-glucuronide). Comparatively,
values for major metabolites identified in this method, (C-5-O-glucoronide and 3’-O-Me5-O-glucornide) were 1.29 and 0.51, respectively. Overall these data are consistent with
that of a highly reproducible analytical method.
Calculated LOD (defined as 3:1 signal:noise) ranged from 1.03-3.41 fmoles on
column for metabolites of catechin and epicatechin compared to 55.5 and 48.4 pmoles
on column for parent compounds catechin and epicatechin, respectively. This suggests
the potential for more efficient ionization of metabolites relative to parent compounds.
These values translated to LOQs of 2.1-10.6 fmol on column or ~11-53 fmol per mL of
plasma for metabolites.
Finally, the analyses were repeated at a second site, using the identical column
and separation parameters, but a different mass spectrometer (see Materials and
Methods). The C and EC metabolites in the plasma were resolved by HPLC with very
similar profiles to those recorded previously. Calibration with authentic standards
resulted in absolute values and standard deviations that closely matched the results
from the first site analyses, with the exception of MCG24 (3’-O-Me-C-5-O-glucoroide),
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which was determined based on calibration with the corresponding 7-O-gluconide. It
was observed that the C and EC metabolites were unstable in thawed plasma samples,
as recently reported elsewhere (Zhang et al., 2013), such that reproducible results were
only obtained if the samples were injected onto the HPLC within a few hours. Samples
left at room temperature were almost totally degraded after 3 days.

Figure 7. Chromatographic separation of and identification of C/EC metabolites for each
mass transition. Peak identification: (a) CG14, 7-glucr; (b) CG18, 5-glucr; (c) MCG19, 7glucr; (d) MCG24, 5-glucr; (e) 3’OMe-EC-5-glucr.
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2.3.6 Advantages and Disadvantages of the Present Approach
Alternative approaches for identifying metabolites of flavan-3-ols in biological
fluids have wither generated standard compounds by chemical synthesis (GonzálezManzano et al., 2009) or attempted to identify the compounds directly from the fluids
(Abd El Mohsen et al., 2002; Natsume et al., 2003; Piskula and Terao, 1998; Spencer,
2003); most of these previous approaches have only unequivocally identified a subset of
the metabolites present. A recent study has reported the chemical synthesis and full
characterization of a complete range of EC glucuronides and sulfates (Zhang et al., 2013).
Such compounds will be of great value for future studies on bioavailability, although
their chemical synthesis is complex, requiring as a starting point the availability of a
complete series of orthogonally protected EC derivatives.
The present study as combined a semisynthetic/biosynthetic scheme with
matching of compounds to authentic metabolites. Although the glucuronosyl
transferase enzymes are not completely regionspecific their mammalian origin means
that they can generate physiologically relevant metabolites, and the matching of
synthetic compounds to plasma metabolites prior to final purification means that only
those metabolites that are physiologically relevant are pursued. Furthermore, an
enzymatic strategy has advantages of the facile introduction of radiolabel, for examples,
in the methyl (from S-adenosyl-L-methionine) or glucuronide (from UDP-glucuronic acid)
moieties, should labeled compounds be required for mechanism of action studies or
analytical internal standards. The limiting step from a cost perspective are the price of
the enzymes, which cannot by recycles, and the cost of UDP-glucuronic acid. Now that
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standards of all glucuronidated metabolites are available for subsequent identification
of products, this problem could be circumvented by a total biological synthesis using
recombinant enzymes express in E. coli, as we have previously shown for synthesis of
flavonol and isoflavone glucosides (He et al., 2008). It should be notes that the present
work does not address the sulfated derivatives that also arise from mammalian
metabolites of flavan-3-ols , particularly in humans (Ottaviani et al., 2012).
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CHAPTER 3. DIFFERENTIATED CACO-2 CELL MONOLAYERS EXHIBIT ADAPTATION IN
TRANSPORT AND METABOLISM OF FLAVAN-3-OLS WITH CHRONIC EXPOSURE TO
BOTH ISOLATED FLAVAN-3-OLS AND ENRICHED EXTRACTS

As part of the manuscript submitted to Food & Function, BW Redan and MG Ferruzzi,
Purdue University, Departments of Nutrition Science and Food Science

3.1

Introduction

Flavan-3-ols are key flavonoids widely distributed in the food supply and are
naturally abundant in foods such as tea, cocoa, and grape. These compounds include
monomeric forms such as catechin (C) and epicatechin (EC), along with complex
proanthocyanidin (PAC) oligomers and polymers, present in grape and cocoa.
Additionally, gallated forms including epigallocatechin gallate (EGCG) and epicatechin
gallate (ECG) are abundant in tea. Data from epidemiological studies supports the view
that diets rich in flavan-3-ols are associated with a decreased risk of specific chronic
diseases including cardiovascular disease (Tresserra-Rimbau et al., 2014), diabetes
(Zamora-Ros et al., 2013a), and certain types of cancers (Zamora-Ros et al., 2013b).
Supporting these epidemiological associations, flavan-3-ols, and especially EC, have
demonstrated ability to improve clinical markers related to cardiovascular function such
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as blood pressure, cholesterol, and flow-mediated dilation (Hooper et al., 2012; Sansone
et al., 2015). However, translation of flavan-3-ols for use in disease-preventative
strategies is limited by several factors including the notion that, excluding microbial
metabolites, <5% of the parent compound is typically absorbed from an oral dose
(Neilson and Ferruzzi, 2011). This is particularly true in the case of bioavailability
assessed from an acute dose, the most predominate experimental paradigm.
While acute bioavailability studies are most common, evidence does exist that
longer-term exposure to flavan-3-ols that is more representative of widespread dietary
exposure or chronic consumption of flavan-3-ol-rich foods can significantly enhance
overall bioavailability in humans and experimental animals. Ten day administration of a
grape seed extract product (GSE) to Sprague-Dawley rats was found to improve plasma
response of C and EC by greater than 250% (Ferruzzi et al., 2009). Similarly, chronic GSE
treatment in rodents increased phase II metabolites as much as 600-700% for C/EC
glucuronides and approximately 140-240% for methyl-C/EC-glucuronides (Wang et al.,
2012). In addition, clinical research has demonstrated that 4 week chronic
administration of 800 mg EGCG per day before a pharmacokinetic assessment results in
EGCG plasma AUC values 60% greater than those not given EGCG (Chow et al., 2003).
Collectively these data suggest that single acute pharmacokinetic assessments may not
fully represent the complex response observed from longer-term dietary exposure.
Having been observed in both pre-clinical and clinical paradigms, the implication of this
adaption remains to be better understood and perhaps leveraged in a manner
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consistent with understanding the bioavailability of flavan-3-ols from longer-term
dietary patterns.
While the exact mechanisms behind this phenomenon are not completely
understood, what is known is that upper intestinal absorption and metabolism of
flavonoids rely on both inducible and non-inducible metabolizing and transport systems
(Croom, 2012) that may be impacted by previous exposure to these compounds. Since
the gastrointestinal tract is the main barrier to delivery of flavonoids, we hypothesize
that adaptation occurring in the upper gastrointestinal epithelium is largely controlling
absorption of ingested compounds and may be partially responsible for the observed
increase in flavan-3-ol absorption and metabolism with chronic exposure. Though gut
microbiota have been reported to affect systemic delivery of phenolic compounds
(Tomás-Barberán et al., 2014), we are focusing here on parent flavonoids and their
Phase II metabolites since their relevance to bioactivity has been more widely studied.
Differentiated Caco-2 monolayers are highly predictive of human absorption and
have been employed to study absorption of a number of pharmaceuticals and
phytochemicals because they form enterocyte-like cells (Sambuy et al., 2005). However,
many studies involving the Caco-2 model are limited to acute studies (Hubatsch et al.,
2007) and do not consider how chronic exposure typical of dietary patterns modulates
cellular processes associated with transport across the gut epithelium. Therefore, Caco2 cell monolayers were exposed throughout differentiation to isolated flavan-3-ols and
extracts rich in flavan-3-ols to determine if adaptation in transport and metabolism of
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these compounds could be induced in this widely-utilized model to better mimic the in
vivo phenomenon.
3.2

Materials and Methods
3.2.1 Materials

Authentic standards of (-)-epicatechin, (+)-catechin, (-)-epigallocatechin gallate,
and (-)-epigallocatchin were obtained from Sigma (St. Louis, MO). Teavigo® (>90% EGCG)
was used for cell culture treatments. Green tea extract was provided by Nestlé
(Marysville, OH) and grape seed extract (MegaNatural-BP®, Polyphenolics, Madera, CA)
was purchased from an online retailer. Solvents for liquid chromatography were of mass
spectrometry grade and all other reagents were either cell culture or at least analytical
grade.

3.2.2 Cell culture and treatments
Caco-2 TC7 cell line (passages 81-84) was maintained in DMEM media with 10%
v/v FBS, 1% v/v nonessential amino acids, 1% v/v HEPES, 1% v/v penicillin/streptomycin,
and 0.1% v/v gentamicin. Cells were incubated at 37°C under a 5% CO2/95% air
atmosphere at constant humidity. For two compartment model experiments, cells were
seeded at a density of 3.2 x 104 cells/mL onto 6-well plates and allowed to differentiate
over a period up to 12 d post-confluency. For cells cultured on Transwell® inserts
(Corning® polyester membrane, 24 mm diameter, pore size 0.4 μm), cells were seeded
at a density of 2.12 x 105 cells/cm2 and differentiated over a period of 21-25 d postconfluency. Cells treated with isolated compounds were cultured in growth media with

66
0 μM (control), 1 μM, or 10 μM of EC or EGCG added to the apical chamber (see Figure 8
for outline of experimental design). Preliminary experiments indicated that cell
monolayers could be treated with these concentrations without significantly decreasing
cell viability (>95%) as determined by MTT assay (Biotium, Hayward, CA). Cells treated
with extracts were cultured in growth media containing GTE rich in EGCG and ECG or
GSE rich in C and EC monomers and polymers. Media was prepared using the same
concentrations as pure compounds as determined by the Folin-Ciocalteu total phenolic
method (Waterhouse, 2001) and changed every 48 h.
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Figure 8. Experimental design to simulate chronic treatment of Caco-2 cell monolayers.
Cells were cultured in growth media with either 0 μM (control), 1 μM, or 10 μM of EGCG,
EC, green tea, or grape seed extract added to the apical chamber. After all cell
treatments were cultured in control media for 24 h, transport was assessed over 4 h in
the three compartment model with a 100 μM acute dose of green tea or grape seed
extract, while uptake and metabolism was assessed over 90 min in the two
compartment model using a 50 μM acute dose. Abbreviations: GTE, green tea extract;
GSE, grape seed extract; EGCG, epigallocatechin gallate; EC, epicatechin.

3.2.3 Flavan-3-ol transport, uptake, and metabolism
After a 24 h washout period in control growth media, cell monolayers were
rinsed with 0.1% fatty-acid free albumin in PBS, followed twice with PBS only. Uptake
and metabolism of pure compounds was assessed by an acute dose of 50 µM EC or
EGCG in PBS (adjusted to pH = 5.5), and cells were harvested at 0 (media immediately
removed after loading onto monolayer), 10, 30, 60, and 90 min. Transport of GTE and
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GSE flavan-3-ols using the Transwell® system was assessed by an acute dose of 100 µM
total phenolics in PBS (pH = 5.5). 1 mL basolateral media was collected and replaced
with fresh PBS at 0, 15, 30, 60, 120, and 240 min. Experiments were performed in
triplicate. After the uptake period, cells were rinsed according to the above procedure
and then collected in ice cold PBS (pH = 5.5). The bicinchoninic acid (BCA) method using
a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA) was used to
determine protein levels.

3.2.4 Cell extraction and transport media preparation
Cells were lysed by sonification for 10 s, after which 1 mL of PBS and MeOH were
added. Cells were extracted three times with 0.01% w/v BHT/ethyl acetate, organic
layers were pooled, and then evaporated under a nitrogen stream. The extract was
resolubilized in 100 μL of 80:20 0.4% formic acid (aq.): acetonitrile (0.1% formic acid)
(v:v) and then centrifuged at 18,000 g for 5 min to remove particulates before injecting
20 μL in the LC-MS-TOF system. Transport media was acidified with 1% v/v formic
acid/acetonitrile, left on ice for 10 min to precipitate proteins, centrifuged, and injected
as described above.

3.2.5 Characterization of flavan-3-ols and metabolites
Parent compounds and metabolites were separated using a Waters RP-C18
column (Xbridge BEH Shield, 2.5 µm, 2.1x100 mm) and characterized using an Agilent
1100 high-pressure liquid chromatography system in tandem with a Waters LCT Premier
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time-of-flight mass spectrometer (LC-TOF-MS) with electrospray ionization (ESI) in
negative mode. Flow was set to 0.25 mL/min and mobile phases were A: 0.4% formic
acid (aq.); B: acetonitrile (0.1% formic acid). Gradient conditions were 5% B at 0 min, 35%
B at 15 min, 70% B at 17 min, 5% B at 19 min, and 5% B at 23 min to reset the gradient.
Extracted ion chromatograms (EICs) m/z are shown in Tables 7 and 8. Standard curves
were produced using standards of parent compounds (C, EC, EGCG, and EGC) and were
used to quantify intracellular/transported compounds in addition to estimating
intracellular metabolite concentrations.
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Table 7. Green tea (GTE) and grape seed extract (GSE) transport loading media flavan-3ol composition (100 μM total phenolics). Values shown are displayed as average ± SD (n
= 3).
Compound

m/z [M-H]

GTE
μM ± SD

GSE
μM ± SD

Catechin
(C)

289

4.83 ± 0.48

3.25 ± 0.62

Epicatechin
(EC)

289

21.9 ± 1.0

6.34 ± 1.23

Epigallocatechin
(EGC)

305

35.2 ± 1.9

Not quantified

Epicatechin gallate
(ECG)

441

0.94 ± 0.050

Not detected

Epigallocatechin gallate
(EGCG)

457

24.1 ± 1.2

Not detected

Proanthocyanidin dimer B2
(PAC B2)

577

Not detected

2.49 ± 0.42

86.9

12.1

TOTAL

-

3.2.6 Data analysis
Values for cellular accumulation of flavan-3-ols and metabolites are expressed as
average pmol ± SEM. Linear regression using Excel was performed to determine the
slope for use in rate calculations (Microsoft, Redmond, WA). The apparent permeability
coefficient (Papp) was calculated using an equation for use in Caco-2 transport studies
(Hubatsch et al., 2007). Analysis was performed using SAS 9.3 (SAS Institute, Cary, NC),

71
and significant differences were evaluated by a Bonferroni post-hoc pairwise test (α =
0.05).

3.3

Results

3.3.1 Monomeric flavan-3-ol composition of extracts and stability to experimental
conditions
GTE shows a similar profile of flavan-3-ols as previously reported (Neilson et al.,
2010), with the major compounds being EGCG and EGC (Table 7). Concentrations of
these compounds in this extract though appear to have lower amounts of gallated with
respect to non-gallated flavan-3-ols. Average recovery of flavan-3-ols over 4 h in cellfree transport media was 92.1%. Table 7 shows the concentrations of C, EC, and PAC B2
in the transport media, which was within the range of that previously reported (Villani
et al., 2015). Average recovery of these flavan-3-ols over 4 h in cell-free transport media
was 79.5%.

3.3.2 Differential cellular uptake and metabolism of flavan-3-ols
In addition to unmetabolized EGCG and EC, methylated and sulfonated
metabolites of these compounds were detected in Caco-2 cells. Figure 9 shows
representative chromatograms of intracellular EGCG, EC, and their metabolites, which is
similar to previous reports of Caco-2 cell metabolism of flavan-3-ols (Sanchez-Bridge et
al., 2015; Zhang et al., 2004). After 30 min, 1 μM EGCG pretreated monolayers showed
significantly (P < 0.05) greater accumulation of EGCG compared to control (80.8 vs. 189

72
pmol/mg protein; control vs. 1 μM pretreatment), but no other differences in
accumulation were observed (Figure 10). While there was no alteration in the rate of
EGCG uptake or methylated EGCG appearance with treatments, 10 μM EGCG
pretreatment decreased appearance rate of both sulfated (0.27 vs. 0.063 pmol∙min-1∙mg
protein-1; control vs. 10 μM pretreatment; P < 0.01) and methyl sulfate derivatives (0.23
vs. 0.070 pmol∙min-1∙mg protein-1; control vs. 10 μM pretreatment; P < 0.05) compared
to control (Table 8).
After 60 min, both 1 and 10 μM EC pretreatments resulted in significantly (P <
0.05) greater EC accumulation compared to control (221 pmol/mg protein, control; 376
pmol/mg protein, 1 μM pretreatment; 352 pmol/mg protein, 10 μM pretreatment), with
the 1 μM pretreatment remaining significantly greater after 90 min (273 vs. 569
pmol/mg protein; control vs. 1 μM treatment). Similarly, both treatments displayed
significantly (P < 0.05) greater levels of methylated EC derivatives after 60 min (38.5
pmol/mg protein, control; 64.4 pmol/mg protein, 1 μM pretreatment; 71.2, 10 μM
pretreatment; pmol/mg protein), with the 10 μM pretreatment showing approximately
twice the concentration of methylated EC at 90 min (46.5 vs. 101 pmol/mg protein;
control vs. 10 μM pretreatment; P < 0.05). Rate of cell accumulation of EC and its
metabolites over 90 min showed that while 10 μM pretreated monolayers had a
significantly increased rate of EC methylation (0.43 vs. 1.03 pmol∙min-1∙mg protein-1;
control vs. 10 μM pretreatment; P < 0.01) there was decreased appearance of sulfated
derivatives (0.90 vs. 0.53 pmol∙min-1∙mg protein-1; control vs. 10 μM pretreatment; P <
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0.05). No significant differences were observed in the rate of appearance of methylatedEC sulfate metabolites with pretreatment.

Figure 9. Representative chromatograms of intracellular EGCG, EC, and their respective
metabolites. Tentative identification of peaks: a, EGCG; b, Me-EGCG; c, EGCG-S; d, MeEGCG-S; e, dimethyl-EGCG; f, EC; g, 3’methyl-O-EC; h, 4’-O-methyl-EC; i, EC-S; j, Me-EC-S.

3.3.3 Differential alteration in transport of flavan-3-ol-rich extracts across Caco-2
monolayers
Since major flavan-3-ol Phase II metabolites of the parent compounds were not
observed to a great extent in the three compartment model, we focused on tracking the
parent compounds for flux through the cell monolayers. Figure 11 shows that after 4 h,
10 μM GTE pretreatment resulted in 38% greater cumulative transport of EC compared
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to control (12.1 vs. 16.7 nmol; control vs. 10 μM pretreatment; P < 0.05). GTE
pretreatment resulted in significant (P < 0.05) differences in transport of gallated flavan3-ols at 60 min, with approximately 60% greater cumulative transport of EGCG (0.56 vs.
0.89 nmol; control vs. 1 μM pretreatment) and a 44-61% increase in ECG transport (0.16
nmol, control; 0.26 nmol, 1 uM pretreatment, 0.23 nmol, 10 uM pretreatment). For
monolayers pretreated with 10 μM grape seed extract, there was significantly (P < 0.05)
greater cumulative transport of C (2.0 vs. 3.1 nmol; control vs. 10 uM pretreatment), EC
(5.4 vs. 6.3 nmol; control vs. 10 uM pretreatment), and PAC B2 (1.0 vs. 1.5 nmol; control
vs. 10 uM pretreatment) after 4 h (see Figure 11). No significant differences were
observed in cellular accumulation of flavan-3-ols with tea or grape seed extract
treatments (data not shown).
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Figure 10. Effect of pretreatment on Caco-2 uptake and metabolism of EGCG and EC
over 90 min was assessed using monolayers differentiated in a 6-well two compartment
model. Monolayers were exposed to either 0 μM (control), 1 μM or 10 μM EGCG or EC
pretreatment (PT) in growth media following the paradigm and conditions described in
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(Figure 10 caption, con’d.) Parent compounds, along with the methylated and
sulfonated metabolites were identified by LC-TOF-MS. *P < 0.05 compared to control.

Figure 11. Chronic pretreatment with green tea extract differentially alters
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(Figure 11 caption, cont’d.) apical to basolateral transport of flavan-3-ols across
differentiated Caco-2 cell monolayers. Confluent Caco-2 monolayers were cultured on
Transwell® inserts in pretreatment (PT) media containing either 0 μM (control), 1 μM, or
10 µM total green tea or grape seed phenolics (see Table 1 for composition of transport
media) during the differentiation process. All cell monolayers were incubated with
control media 24 h before transport was assessed using a 100 µM total phenolics acute
dose of total green tea or grape seed extract over 4 h. Statistical pairwise comparison
was performed comparing 0 µM (control) to treatments. *P < 0.05 compared to control.
Abbreviations: PT, pretreatment; C, catechin; EC, epicatechin; ECG, epicatechin gallate;
EGC, epigallocatechin; EGCG, epigallocatechin gallate; PAC B2, proanthocyanidin B2.

Figure 12. Pretreatment Increases Transepithelial Electrical Resistance (TEER) values.
Caco-2 cells grown on Transwell® inserts (n = 3) were pretreated with either 0 (control),
1, or 10 µM total phenolics of green tea extract (GTE) or grape seed extract (GSE)
indicating an increase in formation of cellular tight junctions. Differing letters indicate
significant difference (P < 0.05) within treatment type.

78
Table 9 displays the apparent permeability coefficient (Papp) calculated from the
transcellular flux of each parent flavan-3-ol compound from green tea and grape seed
extracts. After 2 h, 1 μM GTE pretreated monolayers showed greater (P < 0.01) Papp of C
(7.05 x 107 cm/s vs. 4.93 x 107 cm/s; control vs 1 μM pretreatment) and EC (5.23 x 107
cm/s vs. 7.64 x 107 cm/s; control vs 1 μM pretreatment) compared to control, though
there was a tread in significance for increased EC Papp with 10 μM pretreatment (P =
0.0599). Similarly, significant (P < 0.05) differences in C transport were observed over 2
h in monolayers receiving 10 μM GSE pretreatment (6.54 x 107 cm/s vs. 7.46 x 107 cm/s;
control vs 1 μM pretreatment). Additionally, there was a trend (P = 0.0515) for
increased PAC B2 Papp over 4 h with 10 μM GSE pretreatment. Interestingly, 10 μM
pretreatment with both green tea and grape seed extracts significantly (P < 0.05)
increased transepithelial electrical resistance (TEER) of differentiated monolayers
compared to control (Figure 12).
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Table 8. Rate (pmol/min) of differentiated Caco-2 cell accumulation of EGCG/EC and
formation of EGCG/EC Phase II metabolites in pretreated monolayers compared to
control.a
Compound

EGCG

Methyl-EGCG

EGCG Sulfate

Methyl-EGCG
Sulfate

EC

Methyl-EC

EC Sulfate

Methyl-EC
Sulfate

a

-

m/z [M-H]

457

471

537

551

289

303

369

383

Pretreatment

Rate of cell accumulation ± SEM
-1

-1

(pmol∙min ∙mg protein ) over 90 min

0 µM

3.67 ± 0.334

1 µM

3.67 ± 0.337

10 µM

2.67 ± 0.334

0 µM

3.33 ± 0.334

1 µM

3.67 ± 0.334

10 µM

3.00 ± 0.578

0 µM

0.267 ± 0.0334

1 µM

0.367 ± 0.0667

10 µM

0.0633 ± 0.0120**

0 µM

0.233 ± 0.0334

1 µM

0.600 ± 0.0578**

10 µM

0.0700 ± 0.0173*

0 µM

3.00 ± 0.578

1 µM
10 µM

6.00 ± 1.01
5.00 ± 4.33

0 µM

0.433 ± 0.0667

1 µM
10 µM

0.833 ± 0.120*
1.03 ± 0.0334**

0 µM

0.900 ± 0.0578

1 µM

2.00 ± 0.578

10 µM

0.533 ± 0.0667*

0 µM

0.0533 ± 0.0241

1 µM

0.153 ± 0.0467

10 µM

0.0120 ± 0.00405

#

Values are presented as average (n = 3) ± SEM. Statistical pairwise comparison is between pretreatments

and 0 µM. *P<0.05; **P<0.01; #P=0.0602.
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Table 9. Apparent permeability coefficients (Papp) of green tea (GTE) or grape seed (GSE)
extract flavan-3-ols across differentiated Caco-2 cell monolayers.a
Compound

C
(GTE)

EC
(GTE)

EGCG
(GTE)

ECG
(GTE)

EGC
(GTE)

C
(GSE)

EC
(GSE)

PAC B2
(GSE)

a

Pretreatment

7

7

Papp ± SEM (x 10 cm/s) over 2 h Papp ± SEM (x 10 cm/s) over 4 h

0 µM

4.93 ± 0.336

6.32 ± 0.274

1 µM

7.05 ± 0.0966**

6.48 ± 1.30

10 µM

8.45 ± 3.24

5.86 ± 0.382

0 µM

5.23 ± 0.389

6.57 ± 0.652

1 µM

7.15 ± 0.117**

6.28 ± 0.798

10 µM

7.64 ± 0.834

#

7.18 ± 0.105

0 µM

2.64 ± 0.322

2.47 ± 0.216

1 µM

2.68 ± 0.370

2.51 ± 0.314

10 µM

2.65 ± 0.157

2.72 ± 0.0715

0 µM

9.18 ± 0.896

9.44 ± 0.801

1 µM

10.8 ± 1.28

9.37 ± 1.03

10 µM

9.87 ± 0.666

9.76 ± 0.211

0 µM

4.80 ± 0.809

4.61 ± 0.243

1 µM

5.04 ± 0.438

4.48 ± 0.117

10 µM

4.97 ± 0.348

0 µM

6.54 ± 0.441

5.79 ± 0.285

1 µM

4.75 ± 0.0912

5.47 ± 0.0237

10 µM

7.46 ± 1.39*

8.79 ± 1.04

0 µM

6.94 ± 0.980

7.90 ± 0.101

1 µM

6.01 ± 0.222

6.89 ± 0.549

10 µM

10.3 ± 3.05

9.47 ± 0.651

0 µM

6.02 ± 0.703

4.23 ± 0.0297

1 µM

6.45 ± 1.79

3.84 ± 1.96

10 µM

7.31 ± 0.896

6.07 ± 0.453

5.24 ± 0.163

##

†

Values are presented as average (n = 3) ± SEM. Statistical pairwise comparison is
between pretreatments and 0 µM. *P<0.05; **P<0.01; #P=0.0588; ##P=0.0991;
†
P=0.0515.
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3.4

Discussion

The Caco-2 human intestinal cell model is commonly used to investigate factors
impacting absorption and to a certain extent metabolism of dietary flavonoids. However,
typical experimental paradigms used in cell-based studies rely on acute exposures that
may not mimic chronic dietary exposure to flavonoids. The extent to which the Caco-2
model can exhibit adaptive responses similar to those observed in humans and
experimental animals is critical to establish in order to enhance the predictive nature of
this important model. Our data suggest Caco-2 cell human intestinal cell monolayers
may, in fact, adapt differentially to transport of gallated versus non-gallated flavan-3-ols
with exposure to these phenolics during differentiation. While non-gallated flavan-3-ols
(C and EC) generally exhibited greater levels of cumulative transport at later time points
with pretreatment (2-4 h; see Figure 10), gallated flavan-3-ols (EGCG and ECG) showed
differences in transport and accumulation at 30 and 60 min time points (See Figures 10
and 11). Since gallated flavan-3-ols are less bioavailable as compared to nongallated,(Zhang et al., 2004) these points where alterations in transport and
accumulation occurred may be a reflection of different absorption efficiencies or
perhaps transport mechanisms being affected by chronic exposure to gallated and nongallated flavan-3-ols. Similarly, Caco-2 cell monolayers pretreated with grape
anthocyanins for 96 h exhibit approximately 50% greater transport of these compounds
compared to untreated cells (Faria et al., 2009), indicating that different classes of
flavonoids may induce an adaptive response.
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Still, permeability coefficients of the transported flavan-3-ols (see Table 9)
corresponds with previous values reported in literature (Zhang et al., 2004) and are
indicative of their low oral bioavailability (Papp < 2 x 10-5) (Hubatsch et al., 2007). Since
pretreatment with both extracts significantly increased TEER values, this suggests that
pretreatment impacted tight junction proteins and that the observed increases in
flavan-3-ols transcellular flux are not mediated by paracellular transport. An increase in
tight junction proteins has similarly been observed in rodents treated with grape seed
extract (Goodrich et al., 2012), which may be linked to this treatment resulting in a
reduction of a marker of gut neutrophil infiltration in these animals.
Though there were no differences in intracellular methylated EGCG
concentrations with pretreatment, there was a significantly decrease in formation rate
of both sulfate and methyl sulfate metabolites with 10 µM pretreatment. These data
suggest a inhibitory effect of flavan-3-ol pretreatment on these processes, as flavonoids
have been reported to inhibit sulfotransferases (James and Ambadapadi, 2013). This is
in contrast to a report of HepG2 hepatocytes pretreated for 24-48 h with 10 µM
resveratrol that showed increased gene and protein expression of sulfotransferase
enzymes (Lançon et al., 2007). This suggests that class of the phenolic used in
treatments and length of treatment time combined with tissue type may be critical to
consider in assessing their influences on Phase II metabolizing systems. Though we
observed transient increases in transport with EGCG pretreatment, an animal study with
a two-week pretreatment of 0.32% EGCG diet observed an approximately 50%
reduction in EGCG plasma AUC (James et al., 2015). However, his study did not measure

83
metabolites of the compound and it is possible that enhanced metabolism could be
responsible for the reduction in levels of circulating native EGCG. In contrast, a clinical
study with a two week run-in period providing 800 mg EGCG per day resulted in ≈60%
increase in plasma AUC (Chow et al., 2003), indicating that there may be a differential
response to pretreatment depending on the specifics of the experimental design.
In contrast to EGCG pretreatment decreasing metabolizing systems, there was
significantly greater concentrations of methylated EC metabolites with pretreatment at
60-90 min (Figure 10). Since 10 µM pretreatment did not significantly increase
intracellular concentrations of EC but methylated EC did increase, the increase in
methylated EC levels may not simply be due to increased intracellular levels of the
parent compound but may in fact reflect induction of methylation systems or EC being
preferentially trafficked to these systems for more efficient conjugation. However, this
was not fully assessed in these experiments and remains to be investigated. In contrast,
we observed a significantly lower appearance rate of EC sulfate metabolites with 10 µM
pretreatment compared to control (Table 8), suggesting differential regulation of the
individual Phase II systems with pretreatment. Taken together, changes in metabolism
of phenolic compounds occurring in intestinal tissues with chronic exposure may shift its
metabolism to other tissues such as the liver which then may then results in an altered
systemic metabolite profile.
We were not able to detect glucuronide metabolites of flavan-3-ols using our
model, though some (Rodriguez-Mateos et al., 2014) but not others (Sanchez-Bridge et
al., 2015) have been able to detect this metabolite. This may be related to differences in
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analytical methods used in addition to varying cell culture conditions, treatment
concentrations, and length of treatment times. In addition, we did not observe
significant levels of metabolites in the three compartment model. Again, this may be
related to our use of extracts rather than isolated compounds, which may provide
additional substrate that saturate the metabolizing systems (Sanchez-Bridge et al., 2015).
In comparing our results to in vivo models, we did not observe a similar magnitude of
effects in the adaptive response in our cell model as compared to animal studies
previously cited (Ferruzzi et al., 2009; Wang et al., 2012). This may be due, in part, to
differences in the pretreatment concentrations used in the studies and the actual
concentrations employed in the animal studies. Luminal concentrations in the cited
animal studies are estimated to be in the order of ≈4.3 mM concentrations of
monomeric (epi)catechins (Kararli, 1995), in contrast to the lower pretreatment
concentrations used in our study (1-10 µM). Thus our experimental paradigm may be
more indicative of modest dietary consumption of flavan-3-ols, while the animal study
represents what may be occurring with exposure to amounts common in dietary
supplements. Though luminal concentration of flavonoids could potentially be higher
from typical servings of foods (Scalbert and Williamson, 2000), relatively low doses were
chosen here were based on preliminary screening of cytotoxicity and to mimic more
modest concentrations of flavan-3-ols achieved by typical consumption in the U.S. (Kim
et al., 2014). Another point to consider is that though we did not quantify
proanthocyanidins in the grape seed extract, they appear to be an important
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component in the observed adaptive response in animal models that occurs with
chronic exposure to C/EC monomers and polymers.
Since differentiation of intestinal cells is influenced by its matrix (Reya and
Clevers, 2005), it is plausible that altering that environment will affect the
differentiation process. In support of this, Caco-2 cells chronically treated with flavan-3ol-rich grape seed and other grape products over ≈30 d exhibit differences in expression
of classic markers of differentiation such as sucrase-isomaltase and aminopeptidase N
(Laurent et al., 2004, 2005). Though the present experiments did not measure markers
of differentiation, we did observe increases in TEER values with treatment, which may
indicate altered differentiation. Also, other tissue types appear to respond to
pretreatment as primary hepatocytes have altered gene expression of organic anion
transporting polypeptides (OATPs) with long-term exposure to select anthocyanins (Riha
et al., 2015). As these markers were not followed specifically in this study, future work
will be required to identify specific proteins that may be altered with pretreatment such
as efflux transporters, which have been reported to be affected by the phenolic acid
caffeic acid (Hong et al., 2015).
A limitation of this model is that it does not consider other tissues involved in
absorption and transport of flavonoids, such as the liver and kidney. In addition, it only
focuses on adaptation occurring in the upper gastrointestinal tract, which does not
incorporate changes in gut microbiota in the lower bowel that may occur with a
flavonoid-rich diet. Ultimately, it is important to consider absorption and metabolism of
these compounds in the context of a diet, where there can be multiple interactions
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between food components and individual flavonoids that can alter metabolism of other
compounds (Zhang et al., 2004; Zhu et al., 2008). Still, these results suggest that
intestinal adaptation to chronic exposure to both isolated flavan-3-ols and extracts rich
in flavan-3-ols can alters flavan-3-ol transport and potentially intestinal barrier function.

3.5

Conclusion

Our data suggest pretreatment with isolated flavan-3-ols and extracts rich in these
compounds are both able to elicit an adaptive response in the Caco-2 cell model that is
directionally reflective of in vivo adaptations previously documented. Since this model is
widely used to predict the bioavailability of phytochemicals, the experimental paradigm
of chronic exposure could possibly allow for more accurate assessment of the
absorption and metabolism of these compounds from exposure due to broad dietary
patterns. In addition to the increased transport of green tea and grape seed flavan-3-ols
observed with pretreatment, differences in EGCG and EC metabolite profile with
pretreatment were observed. These data compare to previous pre-clinical and clinical
studies demonstrating adaptation with chronic exposure to these compounds. Though
not directly assessed in these experiments, increased flux of flavan-3-ols observed after
pretreatment suggests induction of more efficient cellular trafficking of the compounds.
More complex models incorporating aspects of Phase II metabolism other than
intestinal metabolism may assist in elucidating alterations occurring at other tissue sites.
In addition, future studies can further explore this question by determining molecular
mechanisms involved in this adaptive response. Taken together, these results
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demonstrate that the Caco-2 cell model may be used model alterations in intestinal
transport and metabolism that occur with chronic dietary exposure to select flanvan-3ols.
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CHAPTER 4. ADAPTATION IN CACO-2 HUMAN INTESTINAL CELL DIFFERENTIATION
AND PHENOLIC TRANSPORT WITH CHRONIC EXPOSURE TO PHENOLIC-RICH
BLACKBERRY (RUBUS SP.) EXTRACT

As part of the manuscript in review in Molecular Nutrition & Food Research, BW Redan1,
GP Albaugh2, CS Charron2, JA Novotny2, and MG Ferruzzi,1,3
1

Department of Nutrition Science, Purdue University, 2USDA-ARS Beltsville Human
Nutrition Research Center, 3Department of Food Science, Purdue University

4.1

Introduction

Berries are a rich dietary source of bioactive phenolic compounds including
anthocyanins, phenolic acids, flavonols, and flavan-3-ols. Though consensus has not
been reached (Jacques et al., 2015), data from epidemiological studies conducted in
various populations support the notion that diets high in fruits, including berries, are
associated with a decreased risk of chronic disease and overall mortality (Du et al., 2016;
Hjartåker et al., 2015). In addition, data from clinical studies have shown that
consumption of dietary sources of anthocyanins and other flavonoids from berries can
improve risk factors for cardiovascular disease such as blood pressure and lipid profiles
(Kianbakht et al., 2014; Novotny et al., 2015). As such, blackberry (Rubus sp.) was
selected for these studies since it is rich in the anthocyanin cyanidin-3-O-glucoside, the
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aglycone of which is the most common in the food supply and most highly consumed
anthocyanin form (Wu et al., 2006). Blackberries contain primarily cyanidin-3-Oglucoside and do not contain as wide array of anthocyanins, including more structurally
complex acylated forms found in many other berries (Kaume et al., 2012; Wu and Prior,
2005).
Still, translation of such findings to dietary strategies to prevent chronic diseases is
limited by several factors including the poor oral bioavailability of flavonoid compounds
from food. Excluding microbial metabolites, less than 5% of a single acute oral, foodbased dose of flavonoids are commonly reported to be absorbed (Neilson and Ferruzzi,
2011), though higher bioavailability values have been reported for ingestion of purified
flavonoids (Manach et al., 2005). However, bioavailability from single oral doses, the
most typically applied assessment of oral bioavailability, may not be indicative of the
more common dietary paradigm of repeated daily exposure encountered by high
consumers of fruits and vegetables. Evidence does exist that long-term exposure to
flavonoids can significantly alter bioavailability (Chow et al., 2003; Ferruzzi et al., 2009)
and metabolism of flavonoids (Wang et al., 2015, 2012). In an animal study, 10 day
administration of a grape seed extract improved plasma response of catechin
(C)/epicatechin (EC) (Ferruzzi et al., 2009) and C/EC glucuronides and methylglucuronides (Wang et al., 2012). In addition, clinical work has demonstrated that 4
week chronic daily administration of EGCG increased its AUC by approximately 60%
(Chow et al., 2003).
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While an adaptive response to phenolic chronic exposure has been observed in
both pre-clinical and clinical models, the mechanisms behind this phenomenon are not
well understood. Since dietary patterns typically result in a paradigm of chronic
exposure to various phenolic compounds, there is a need to better understand the
adaptive phenomena so they can be leveraged to improve bioavailability and delivery of
key phenolic metabolites related to disease-preventative endpoints. Considering the
gastrointestinal tract is the main barrier to delivering dietary phenolics systemically, we
hypothesize that adaptation occurring in the upper gastrointestinal epithelium is a key
factor modifying absorption of phenolics and may be responsible, in part, for the
observed differences in flavonoid absorption and metabolism in chronic dosing
paradigms.
To gain a better mechanistic understanding of bioavailability, researchers have
utilized differentiated Caco-2 cell monolayers to study transport of pharmaceuticals and
phytochemicals since they are highly predictive of human absorption (Sambuy et al.,
2005). However, most studies involving the Caco-2 cell model are limited to acute
experimental paradigms and do not consider how chronic exposure typical of dietary
patterns modulates physiological activities, such as absorption at the gut epithelium.
Since the Caco-2 model has exhibited differential transport of phenolics in acute versus
a long-term treatment with grape-derived anthocyanins (Faria et al., 2009), we
proposed simulating the chronic treatment paradigm from previous animal studies using
Caco-2 cell monolayers to determine if we could model an adaptive response in
transport of blackberry phenolics.
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4.2

Materials and Methods

4.2.1 Preparation of Blackberry extract
Composite blackberry extract was produced from frozen blackberries, which
were a combination of Rubus laciniatus, Rubus Marion, and Rubus fruticosus L.
purchased from SYSCO (Houston, TX). Blackberries were freeze-dried and then extracted
with methanol:H2O (80:20; v:v) and resulting extracts dried under a nitrogen stream.
Bulk extract was then resoluabilized in H2O:HCl (99.9:0.01; v:v) and purified using an
Extract Clean™ 10,000 mg/75 mL C18-HC column (Grace, Columbia, MD). Briefly, the
column was activated with 1 column volume (75 mL) MeOH, followed by 3 column
volumes H2O. Blackberry extract was loaded onto the column and successively washed
with 4 column volumes H2O to remove ascorbic acid, sugars, and other osmotically
active compounds, dried for 30 s with vacuum, and then eluted with 1 column volume
of MeOH:HCl (99.9:0.01; v:v). The eluate was then aliquoted into glass tubes, dried
under a nitrogen stream, and stored at -80°C until further use.

4.2.2 Cell culture and treatments
Caco-2 TC7 cell line (passages 81-84) was maintained in DMEM media with 10%
FBS with 10% v/v FBS, 1% v/v nonessential amino acids, 1% v/v HEPES, 1% v/v
penicillin/streptomycin, and 0.1% v/v gentamicin. Cells were seeded at a density of 2.12
x 105 cells/cm2 on a Transwell® insert system (Corning® polyester membrane, 24 mm
diameter, pore size 0.4 μm), and monolayers were differentiated over a period of
approximately 25 d post-confluency. Total phenolic concentration of blackberry extract
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was determined by the Folin-Ciocalteu total phenolic method (Waterhouse, 2001) and
sterile filtered (0.2 μm filter). Cells were cultured in growth media with a final
concentration of either 0 μM (control), 1 μM, or 10 μM blackberry phenolics, added to
the apical chamber (see Figure 13 for outline of experimental design). Preliminary
experiments showed that cell monolayers could be chronically treated with 10 μM of
extract without significantly decreasing cell viability (>95%) as determined by MTT assay
(Biotium, Hayward, CA). All growth media was changed every 48 h.

Figure 13. Experimental design to simulate chronic treatment of Caco-2 cell monolayers.
Cells were cultured in growth media with either 0 μM (control), 1 μM, or 10 μM of
blackberry extract added to the apical chamber. After all cells were cultured in control
media for 24 h, uptake was assessed over 4 h with a 100 μM acute dose of blackberry
extract.
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4.2.3 Transport of Phenolic Compounds
Before assessing transport of phenolics, cell monlayers were cultured for 24 h in
control growth media, rinsed twice with 0.1% fatty-acid free albumin in PBS, and
followed with PBS only. Transport of blackberry extract was assessed using an acute
dose of 100 µM total phenolics in PBS transport buffer (pH = 5.5). 1.5 mL transport
media was added to the apical chamber and 2 mL of PBS (pH = 5.5) was initially placed
in the basolateral chamber, after which 1 mL PBS was collected and replaced with fresh
PBS at 0 (immediately collected after transport media was loaded), 30, 60, 90, 120, and
240 min. Experiments were performed in quadruplicate. After the 4 h uptake period,
cells were rinsed according to the above procedure and then collected in ice cold PBS
(pH = 5.5). Transport media was acidified with 1% v/v formic acid/acetonitrile and then
left on ice for 10 min to precipitate protein, and centrifuged at 18,000 g for 5 min to
remove particulates before injecting 20μL in the LC-MS-TOF system. Stability of
compounds in transport media over 4 h was assessed by incubating cell-free transport
media in 6-well plates, and recovery of cyanidin-3-O-glucoside in the media was found
to be 98.1 ± 3.75% (mean ± SEM).

4.2.4 Analysis of Blackberry Extract and Test/Transport Media
Analysis of blackberry extracts and test/transport media was adapted from
methods previously described (Song et al., 2013, 2015). Briefly, separations of phenolics
was achieved using a Waters RP-C18 column (Xbridge BEH Shield, 2.5 µm, 2.1x100 mm)
and characterized using an Agilent 1100 high-pressure liquid chromatography system in
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tandem with a Waters LCT Premier time-of-flight mass spectrometer (LC-TOF-MS) with
electrospray ionization (ESI) in either positive (for anthocyanins) or negative mode (for
other phenolics). The flow was set to 0.25 mL/min and mobile phases were A: 2% formic
acid (aq.); B: acetonitrile (0.1% formic acid) for anthocyanin analysis and A: 0.4% formic
acid (aq.); B: acetonitrile (0.1% formic acid) for other phenolics. A linear gradient
condition for eluting anthocyanins was as follows: initial conditions were 5% B; 0-15 min:
5-25% B; 15-18 min: 25-30% B; 18-19 min: 30-5% B; 19-23.5 min: hold at 5% B to reset
the gradient. Conditions for other phenolics was 5% B at 0 min; 0-15 min: 5%-35% B; 1517 min: 35-70% B; 17-19 min: 70-5% B; hold at 5% B at 23 min to reset the gradient.
Mass-to-charge (m/z) ratios used to produce extracted ion chromatograms (EICs) and
used to characterize and quantify compounds are displayed in Table 10. Cyanidin-3-Oglucoside was characterized using MS and then quantified using photodiode array (PDA)
response at 520 nm. Standard curves using pure standards of cyanidin-3-O-glucoside
(Chromadex, Irvine, CA), (+)-catechin, (-)-epicatechin, quercetin-3-O-glucoside,
kaempferol-7-O-glucoside, and 3-O-caffeoylquinic acid (Sigma, St. Louis, MO) were
produced to quantify transported phenolics.

4.2.5 Gene expression
In order to determine alteration of xenobiotic transport and metabolizing system
gene expression due to chronic exposure, a parallel set of Caco-2 cell experiments was
conducted with cells treated as previously described in Section 2.2. RNA was isolated
using RNeasy spin columns according to the manufacturer’s directions (Qiagen Sciences,
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Germantown, MD). RNA was analyzed by Experion RNA gel electrophoresis (Bio-Rad
Laboratories, Hercules, CA) for its quality and quantity, reverse transcribed to cDNA, and
then plated onto the Drug Metabolism: Phase II Enzymes PCR Array (SABiosciences,
Germantown, MD, catalogue no. PAHS-069Z) and the Drug Transporters PCR Array
(SABiosciences, Germantown, MD, catalogue no. PAHS-070Z), following manufacturer’s
instructions to determine alterations in expression of the respective genes. Real-time
PCR was conducted using a CFX96 real-time PCR system (Bio-Rad laboratories).

4.2.6 Data Analysis
Values for phenolics are expressed as average pmol per well ± SEM (n = 4). The
apparent permeability coefficient (Papp) was calculated using an equation previously
reported using the Caco-2 cell model to measure transport of compounds through the
cell monolayer (Hubatsch et al., 2007). Gene expression values are displayed as average
(n = 3) ∆∆Ct fold-changes in mRNA expression relative to housekeeping genes. Displayed
data were selected by determining genes with significant (P < 0.05) or near significant
changes in expression. Analysis of gene expression data was performed using an Excel
(Microsoft, Redmond, WA) spreadsheet template as provided by SABiosciences. All
other analyses were performed using SAS 9.3 (SAS Institute, Cary, NC), and significant
differences were evaluated by a Bonferroni post-hoc pairwise test (α = 0.05).
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4.3

Results

4.3.1 Differential transport of blackberry phenolics with pretreatment
Phenolic composition of the extract is shown in Table 11. The main anthocyanin
in the blackberry extract was cyanidin-3-O-glucoside, which corresponds to previously
reported values (Kaume et al., 2012; Mertz et al., 2007). Interestingly, this blackberry
preparation did have greater amounts of kaemperfol glycosides and less quercetin
glucoside compared to previous reports (Mertz et al., 2007), but this may simply be due
to differences between geographic origin, harvest season and specific variety. The
molecular ion corresponding to 515 m/z was tentatively identified as dicaffeoylquinic
acid.
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Table 10. Mass-to-charge (m/z) ratios and ionization mode used to characterize phenolic
compounds in treatment and transport media using LC-TOF-MS.
Compound

m/z

Ionization mode

Cyanidin-3-O-glucoside

449

+

Catechin/Epicatechin

289

−

Kaempferol glucoside

447

−

Kaempferol glycoside
derivative

465

−

Quercetin glucoside

463

−

Dicaffeoylquinic acid

515

−

Since major phase II metabolites of the parent compounds found in the
blackberry extract were not observed to a great extent in this model (data not shown),
we focused on tracking the parent compounds for flux through the cell monolayers.
Figure 14 displays cumulative apical to basolateral transport data for the seven major
phenolic species in the blackberry transport media. After 2 h, 1 μM pretreated
monolayers showed significant (P < 0.05) differences in transport including a 34%
decrease in cumulative transport of cyanidin-3-O-glucoside compared to control (0 μM
pretreatment) (7.14 vs. 4.75 nmol; 0 μM vs. 1 μM pretreatment) and 30% less transport
of dicaffeoylquinic acid (6.61 vs. 4.64 nmol; 0 μM vs. 1 μM pretreatment). After 4 h, 1
μM pretreated monolayers were observed to have reduced transport of every phenolic
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compound other than cyanidin-3-O-glucoside including 33% less catechin (0.979 vs.
0.654 nmol; 0 μM vs. 1 μM pretreatment), 42% less epicatechin (2.48 vs. 1.43 nmol; 0
μM vs. 1 μM pretreatment), 19% less kaempferol glucoside (41.1 vs. 31.5 nmol; 0 μM vs.
1 μM pretreatment), 23% kaempferol glycoside derivative (17.5 vs. 14.1; 0 μM vs. 1 μM
pretreatment), 20% less quercetin glucoside (1.90 vs. 1.19; 0 μM vs. 1 μM
pretreatment), and 30% less dicaffeoylquinic acid (20.9 vs. 14.2; 0 μM vs. 1 μM
pretreatment). While there were no significant differences in phenolic transport over 4
h with 10 μM pretreatment, it significantly (P < 0.05) exhibited decreased transport of
kaempferol glucoside (15.2 vs. 12.2 nmol; 0 μM vs. 10 μM pretreatment) and
dicaffeoylquinic acid (6.61 vs. 4.60; 0 μM vs. 10 μM pretreatment) over 2 h. In addition,
a decrease in quercetin glucoside transport was observed after 90 min in the 10 μM
pretreated monolayers compared to 10 μM pretreatment (0.380 vs. 0.197 nmol).
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Figure 14. Chronic pretreatment with blackberry fruit phenolics differentially alters
apical to basolateral transport of blackberry fruit phenolics across differentiated Caco-2
cell monolayers. Confluent Caco-2 monolayers were cultured on Transwell® inserts in
pretreatment (PT) media containing either 0 (control), 1, or 10 µM total blackberry
phenolics (see table 2 for composition of blackberry transport media) during the
differentiation process. All cell monolayers were incubated with control media 24 h
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(Figure 14 caption, con’d) before transport was assessed using a 100 µM acute dose of
total blackberry phenolics over 4 h. Left panel displays uptake data over 2 h while right
panel is over 4 h. Statistical pairwise comparison was performed comparing 0 (control)
to 1 or 10 µM PT. *P < 0.05 compared to control. Abbreviations: PT, pretreatment; Cy-3glc, cyanidin-3-O-glucoside; C, catechin; EC, epicatechin; K-glc, kaempferol glucoside; Kgly, kaempferol glycoside derivative; Q-glc, quercetin glucoside; DCQA, dicaffeoyquinic
acid.
Table 11. Blackberry Transport Loading Media phenolic Composition (100 μM total
phenolics)a
Phenolic class

Compound

μM ± SD

Anthocyanin

Cyanidin-3-O-glucoside

37.70 ± 1.05

Catechin

0.230 ± 0.0213

Epicatechin

3.339 ± 0.107

Kaempferol glucoside

13.119 ± 0.779

Kaempferol glycoside
derivative

8.314 ± 0.258

Quercetin glucoside

2.34 ± 0.14

Dicaffeoylquinic acid

19.80 ± 0.255

TOTAL

84.73

Flavan-3-ols

Flavonols

Phenolic acid

a) Values shown are displayed as average ± SD (n = 3).
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Table 12. Apparent permeability coefficients (Papp) of blackberry phenolics across differentiated Caco-2 cell monolayers.a
Compound

Cyanidin-3-O-glucoside

Catechin

Epicatechin

Kaempferol glucoside

Kaempferol glycoside derivative

Quercetin glucoside

Dicaffeoyquinic acid

Pretreatment

log Papp (cm/s) over 2 h

log Papp (cm/s) over 4 h

0 µM

-7.26 ± 0.855

-6.82 ± 0.846

-7.38 ± 0.875**

-6.85 ± 0.820

-7.36 ± 0.856*

-6.77 ± 0.778

0 µM

-6.33 ± 0.740

-6.18 ± 0.761

1 µM

-6.33 ± 0.744

-6.34 ± 0.760**

10 µM

-6.36 ± 0.713

-6.25 ± 0.726#

0 µM

-6.97 ± 0.808

-6.77 ± 0.802

1 µM

-7.00 ± 0.837

-6.91 ± 0.816**

10 µM

-7.03 ± 0.773

-6.79 ± 0.801

0 µM

-6.44 ± 0.761

-6.31 ± 0.757

1 µM

-6.55 ± 0.790*

-6.42 ± 0.772*

10 µM

-6.57 ± 0.774*

-6.32 ± 0.765

0 µM

-6.55 ± 0.771

-6.48 ± 0.785

1 µM

-6.57 ± 0.799

-6.57 ± 0.785*

10 µM

-6.63 ± 0.805*

-6.49 ± 0.799

0 µM

-7.10 ± 0.794

-7.30 ± 0.754

1 µM

-7.64 ± 0.787*

-7.49 ± 0.775

10 µM

-7.64 ± 0.791*

-7.25 ± 0.749

0 µM

-6.97 ± 0.783

-6.78 ± 0.801

1 µM

-7.17 ± 0.831*

-6.92 ± 0.801*

10 µM

-7.17 ± 0.857*

-6.83 ± 0.811
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1 µM
10 µM
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Table 12 legend.
a) Values are presented as average (n = 4) ± SEM. Statistical pairwise comparison is
between pretreatments and 0 µM.
*P<0.05; **P<0.01; #P=0.0503.

Iterestingly, phenolics were not detectable in cell monolayers after 4 h exposure to any
treatment.
Table 12 displays transport data as log apparent permeability (Papp) calculated
from the rate of each phenolic’s transcellular flux. While log Papp of cyanidin-3-Oglucoside was not affected over 4 h, both pretreatment conditions significantly (P < 0.05)
decreased its log Papp over 2 h from -7.26 cm/s for 0 μM pretreated to -7.38 and -7.36
cm/s for 1 and 10 μM pretreatment, respectively. For flavan-3-ols catechin and
epicatechin, log Papp significantly decreased over 4 h and not 2 h for the 1 μM
pretreatment and reached near significance (P = 0.0503) for catechin transport over 4 h.
For flavonols, kampferol glucoside showed decreased log Papp for both treatments over
2 h but only 1 μM treatment over 4 h, and similar results were found for the kaempferol
glycoside derivative. Quercetin glucoside exhibited significantly decreased log Papp for
both treatments at 2 h but not 4 h. Lastly, dicaffeoyquinic acid showed decreased log
Papp for both treatments over 2 h but only 1 μM pretreatment reached statistical
significance over 4 h.
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4.3.2 Differential changes in mRNA expression of xenobiotic transport and
metabolizing systems
Figure 15 displays alterations in expression of xenobiotic metabolizing system
genes with 4 h 100 μM acute treatment only and 10 μM pretreatment plus 100 μM
acute treatment compared to differentiated cell monolayers. These data show
significant (P < 0.05) alterations in gene expression related to Phase II metabolism
including methylation, sulfation, and glucuronidation for both treatments. However, six
out of the 15 genes displayed in Figure 15 were significantly (P < 0.05) different only
with pretreatment in contrast to cell monolayers solely receiving acute treatment. The
results showed increased expression of one of the three genes UGTs (UGT2B10), while
there was decreased expression of both UGT1A4 and UGT1A8. Gene expression was
altered in four SULT genes, with pretreatment alone resulting in a significant decrease in
SULT2A1 expression. SULT4A1 expression decreased to a greater magnitude with
pretreatment (-4.5 fold) compared to acute treatment only (-1.6 fold). Three
methylation genes (GNMT, HNMT, and TPMT) were significantly altered from the
treatments, but GNMT was only altered with pretreatment.
Figure 16 displays transport genes whose expression was impacted by both the
acute and chronic treatments. Eight out of the 15 transporters displayed were only
significantly (P < 0.05) affected by pretreatment plus acute treatment. Overall, there
was decreased expression of transport systems except SLC7A11, which significantly
increased by almost four fold with pretreatment but not acute treatment.
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Figure 15. Differential alteration in gene expression of Phase II metabolizing enzymes in
differentiated Caco-2 cells due to chronic pretreatment (PT) compared to acute only
treatment with blackberry fruit extract. Values are displayed as average (n = 3) ∆∆Ct
fold-changes in mRNA expression relative to selected housekeeping genes. Statistical
pairwise comparison was performed comparing differentiated Caco-2 cells to
treatments. *P < 0.05 compared to control; #P = 0.056 compared to control; ##P = 0.0501.
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Figure 16. Differential alteration in gene expression of transport systems in
differentiated Caco-2 cells due to chronic pretreatment compared to acute only
treatment with blackberry fruit extract. Values are displayed as average (n = 3) ∆∆Ct
fold-changes in mRNA expression relative to selected housekeeping genes. Statistical
pairwise comparison was performed comparing differentiated Caco-2 cells to
treatments. *P < 0.05 compared to control; #P = 0.063; ##P = 0.0687.

4.4

Discussion

The Caco-2 cell model has been previously used to elucidate mechanism of
absorption and metabolism for phenolics connected by epidemiological associations
between berry consumption and reduced risk of chronic disease. Caco-2 experiments
have demonstrated that blackberries and other berries rich in anthocyanins have been
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characterized to have effects including decreased peroxyl radical production (Elisia and
Kitts, 2008) to decreased gene expression of GLUT2 and SGLT1 (Alzaid et al., 2013). In
addition, the three compartment Caco-2 cell model used in this study has been widely
utilized to assess intestinal transport of flavonoids and phenolic acids from various berry
extracts and has also been done in parallel to clinical studies (Kuntz et al., 2015).
However, characterization of the effect of chronic exposures that mimic dietary patters
rich in berry foods on phenolic transport and metabolism is limited. Since intestinal
enterocytes have a high turnover rate and the nascent cells repopulating the epithelial
lining are influenced by the extracellular matrix (Reya and Clevers, 2005), it is possible
that dietary factors including phenolics can influence the differentiating cell’s function.
Supporting this notion are data demonstrating that Caco-2 monolayers chronically
treated with extracts of grape seed and grape products during the differentiation
process exhibit altered markers of differentiation such as sucrase-isomaltase and
aminopeptidase N (Laurent et al., 2004, 2005), suggesting that the addition of phenolicrich extracts to cellular media is fundamentally altering the cell’s phenotype.
Our data overall show significant (P < 0.05) decreases in the cumulative transport
of phenolic compounds across Caco-2 cell monolayers with pretreatment of berry
extracts in a fashion that mimics the exposure of a chronic dietary pattern rich in berries.
This is in contrast to Faria et al. which showed an approximately 50% increase in
transport of anthocyanins with 96 h pretreatment of phenolic-rich grape skin extract
before assessing transport in Caco-2 cells (Faria et al., 2009). Additionally, these results
differ from animal work done with grape seed extract rich in flavan-3-ols (Ferruzzi et al.,
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2009; Wang et al., 2012) and a human study that administered isolated EGCG (Chow et
al., 2003), which both reported increased bioavailability with chronic exposure. There
are likely several reasons for these differences, one being that Faria et al. pretreated
Caco-2 monolayers with ≈400 µM phenolics (200 µg/mL grape skin anthocyanins), and
the animal and clinical study would have produced concentrations in the gut lumen
estimated to be ≈4.3 mM and ≈900 µM, respectively. While it is possible that luminal
concentration of flavonoids would be higher from typical servings of foods (Scalbert and
Williamson, 2000), relatively low doses were chosen here (1-10 µM) based on
preliminary screening of cytotoxicity and to mimic more modest concentrations
achieved by typical consumption of fruits in the U.S. (approximately 100 g per day) for
both children (Kim et al., 2014) and adults (Kimmons et al., 2009). Thus, use of these
relatively lower concentrations in the current study may partially explain the differences
in the directionality of the observed changes in transport between animal studies and
preclinical cell-based studies here.
Other differences between this study and others assessing phenolic transport
include our use of anthocyanin-rich blackberry extract, which contains a different milieu
of phenolic compounds than those used previously, suggesting that intestinal
adaptation may be dependent on phenolic class and matrix. Additionally, since Caco-2 is
a human intestinal cell line, it is not unexpected for the data to be somewhat different
from animal models. Another consideration for our results is that phenolic extracts were
used in order to isolate the effect of phenolic compounds over non-phenolic compounds
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such as ascorbic acid and sugars, which have both been reported to increase
bioavailability of flavan-3-ols (Peters et al., 2010).

Figure 17. Enterocyte localization of transport proteins affected by blackberry extract
treatments and directional change of its mRNA expression.

There appeared to be greater alteration in transport over 4 h from 1 μM but not
10 μM pretreated monolayers (see Figure 16), which demonstrates that it is critical to
assess transport over a range of time points. The decreases in log Papp values with
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chronic exposure (Table 12) indicates that there may be less absorption of these
compounds in vivo with pretreatment since log Papp values have been reported to
correlate with the fractional absorption of select pharmaceutical compounds in humans
(Hubatsch et al., 2007). As such, this decrease in log Papp values may therefore indicate
decreased intestinal transport with chronic exposure in a clinical setting. Since phenolics
were not detectable in cell monolayers in any treatment group, differences in transport
are likely not due to increased cellular accumulation.
Our data showed differences in gene expression of the Phase II metabolizing
enzymes with blackberry exposure. We observed significant (P < 0.05) decreases in
mRNA expression of Phase II metabolizing enzymes UGT1A4 and borderline significant
(P = 0.0501) decreased expression of UGT1A8 with pretreatment (see Figure 15). This
decrease may be due to the large concentration of glycosylated compounds (for
example, anthocyanin and flavonol glycosides) present in blackberry extract, since
phenolic glycosides have been reported to reduce circulating glucuronidated
metabolites in rodent models and decrease gene expression of UGT1A8 in rat intestinal
tissue (Ma et al., 2013). As such, decreasing glucuronidation systems in the intestine
may shift xenobiotic metabolism to other tissues such as the liver and kidney. Still,
mRNA expression of other Phase II metabolizing enzymes show increased expression
(such as sulfotransferases and methylation enzymes) apparently due to the inducible
nature of these systems. Though Phase II metabolites of the flavan-3-ols have been
reported in Caco-2 cell model (Rodriguez-Mateos et al., 2014; Zhang et al., 2004), we
were unable to detect metabolites, which may be related to their concentrations being
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under the limit of detection of our instrumentation or due to the use of complex plant
extracts rather than isolated phenolics used in previous studies.
Overall, gene expression of transport systems decreased, except for the amino
acid transporter SLC7A11, which increased by more than four-fold (Figure 16). These
decreases in gene expression may partially account for the observed lower cumulative
phenolic transport. Though GLUT2 (SLC2A2) and SGLT1 (SLC5A1) have been shown to be
critical to the absorption of cyanidin-3-O-glucoside in the Caco-2 model (Zou et al.,
2014), these transporters were not significantly affected by treatments and may explain
why transport of this compound was only modestly affected. In addition, gene
expression was only measured after the 4 h acute treatment period, which may have
not captured any differences occurring before this time interval. Localization of these
transporters is also an important factor to consider (see Figure 17) in addition to
molecular interaction of transporters with phenolic compounds, which may not
necessarily be accounted for by gene expression data.
Interestingly, transepithelial electrical resistance (TEER) values significantly (P <
0.05) increased in 10 μM but not 1 μM pretreated monolayers (Table 13), which may
indicate that gut barrier function may be altered through pretreatment by increasing
tight junction proteins. Since the TEER values in 1 μM pretreated monolayers were not
significantly different (P > 0.05) from control, observed differences in transport are likely
due to changes in transport-mediated and not paracellular mechanisms. Apple extracts
have been reported to increase TEER values in Caco-2 cell monolayers (Vreeburg et al.,
2012), along with quercetin (Amasheh et al., 2008).and naringenin (Noda et al., 2013),
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which both upregulate gap junction proteins. In addition to cell culture studies, this
increase in levels of tight junction proteins has similarly been shown in animal models
treated with flavan-3-ol rich grape seed extract (Goodrich et al., 2012).

Table 13. Background-subtracted transepithelial electrical resistance (TEER) values of
differentiated Caco-2 cell monolayers used in transport experiments.a
Pretreatment Condition

TEER (Ω∙cm2)

0 µM

240 ± 4.74a

1 µM

240 ± 7.46a

10 µM

256 ± 4.37b

a) Values are presented as average (n = 4) ± SEM, and those with different letters are
significantly different (P < 0.05).

One limitation of this model is that it does not consider other tissues involved in
transport and metabolism of phenolics, such as the liver. Primary hepatocytes exhibit
altered expression of organic anion transporting polypeptides (OATPs) with longer-term
exposure (24 h) to select isolated anthocyanins (Riha et al., 2015), indicating that this
tissue needs to be considered for future work. In addition, the Caco-2 model only
focuses on adaptation occurring in the upper gut, which does not consider alterations in
gut microbiota that may occur with a diet high in phenolics. Berries have been shown to
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influence gut microbiota in animal (Jakobsdottir et al., 2013; Lacombe et al., 2013) and
human (Vendrame et al., 2011) studies. Further, the gut microbiome has been
reportedly modified by repeated exposure to phenolic-rich grape seed extract, leading
to increased production of low-molecular weight phenolic catabolites with potential
bioactive effects (Wang et al., 2015).

4.5

Conclusion

Our data show there was an adaptive response in the Caco-2 cell model
following a pretreatment period, demonstrating this model is dynamic and may be used
for mechanistic insight into gut physiological responses. Decreased transport of
blackberry phenolics were observed with pretreatment, suggesting that chronic
exposure led to decreased flux through the cell or possibly shifts in metabolism of
phenolics. We also observed changes in expression of xenobiotic transport and
metabolism genes with chronic exposure to blackberry extract that were consistent with
the observed decreased transport of phenolic compounds. Although the transport data
in this study did not appear to correlate to previous animal and clinical studies, this may
be due to differences in phenolic class and matrix of the tested extract. Future studies
should consider exploring methods to develop a model that incorporates other aspects
of human physiology affected by chronic exposure to phenolics, such as the liver and the
gut microbiome. Taken together, these results suggest that intestinal xenobiotic
transport and metabolism are modulated by chronic exposure to phenolic-rich
blackberry extract. Overall, these results indicate that adaptation occurring to the
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intestinal epithelium with chronic exposure to phenolic compounds is critical to consider
for a variety of implications involving absorption. As such, studies assessing
bioavailability with only an acute dose may not be readily translational due to
differences in consumers and non-consumers or diets rich in phenolic compounds.

114

CHAPTER 5. EFFECT OF 3-WEEK BLACKBERRY REPEATED EXPOSURE ON THE
ABSORPTION, METABOLISM, AND EXCRETION OF FLAVONOIDS IN LEAN AND OBESE
HUMANS

5.1

INTRODUCTION

Increased consumption of berry fruits has been associated with a reduced
incidence of certain chronic diseases, such as heart disease and type 2 diabetes (Cassidy
et al., 2013; Muraki et al., 2013). Supporting these associations are clinical studies
linking improvements in markers of heart disease and oxidative stress to berry
consumption (Del Bo’ et al., 2015). Specifically, consumption of blueberry, cranberry and
strawberry have all been reported to improve risk factors for cardiovascular disease
such as high blood pressure, oxidized LDL, lipid peroxidation, and low HDL
concentrations (Basu et al., 2010, 2014; Ruel et al., 2008). Though the mechanism of
action involved in how the components in berries impart their observed beneficial
effects is still a topic of much investigation, it is known that that berries are a rich
dietary source of flavonoids, especially the pigmented anthocyanins, which have been
hypothesized to be involved in exerting their biological activity.
Though not as heavily researched as the aforementioned berries, there is
substantial in vitro work suggesting that blackberry can help prevent risk factors thought
to be involved in cancer and heart disease, such as oxidized lipoproteins and nucleic
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acids (Kaume et al., 2012). In pre-clinical rodent models, blackberry has been
reported to have effects ranging from prevention of bone loss (Kaume et al., 2015) to
decreased systemic blood glucose concentrations (Stefănuţ et al., 2013), while clinically
it may improve risk factors for cardiovascular disease in dyslipidemic populations
(Aghababaee et al., 2015). Since flavonoids appear to have strong potential as the
mediators of the observed beneficial effects of berry consumption, it is critical to fully
understand factors that influence or alter the absorption and excretion of these
compounds, especially in the context of long-term dietary patterns that more closely
resemble those linked to epidemiological associations.
While promising, application of berry-derived anthocyanins and other flavonoids
for use in disease preventative strategies is limited by the notion that, excluding
microbial metabolites, the acute oral bioavailability of intact flavonoids is less than 5%
(Neilson and Ferruzzi, 2011). However, it is important to note that pharmacokinetic
assessments commonly reported for flavonoids and used in of determining their
bioavailability are typically performed using a single acute dose which is not
representative of the chronic exposure resulting from broad dietary patterns. Indeed,
both clinical and pre-clinical research has demonstrated that repeated exposure to
flavonoids in a longer-term fashion resembling daily consumption dietary patterns may
alter bioavailability of these compounds. For example, ten-day repeated administration
of a grape seed extract product in rodents improved plasma response of catechin and
epicatechin by greater than approximately 150% (Ferruzzi et al., 2009; Wang et al.,
2012). Four-week daily administration of 800 mg of the flavan-3-ol epigallocatechin
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gallate (EGCG) per day before an acute pharmacokinetic assessment resulted in plasma
EGCG AUC values approximately 60% greater compared to those not repeatedly
exposed to EGCG. Considering this potential for adaptation, a more complete
understanding of factors driving this effect from whole foods, such as berries, is critical
to best leverage this phenomenon for therapeutic endpoints.
In addition, due to the increasing prevalence of obesity on a global level (Ogden et
al., 2007), it is important to consider how this condition may affect bioavailability of
flavonoids and their specific metabolites. This information is critical to develop targeted
dietary recommendations for these population groups. Certain factors associated with
obesity have been implicated in possibly altering the bioavailability or bioactivity of
these compounds (Xiao and Högger, 2014), including alteration of gut function and
modulated gut bacterial populations that may affect production of various bioactive
metabolites (Selma et al., 2015). Additionally, obesity has been associated with
decreased status of both fat-soluble (vitamin K, β-carotene and tocopherol) and watersoluble micronutrients (folate), suggesting that increased BMI may affect absorption
and/or metabolism of dietary compounds (Mahabir et al., 2008; Shea et al., 2010; Wise
et al., 2009). In order to better understand adaptation to repeated berry exposure in
lean and obese participants, the present study tested whether 3-week repeated daily
exposure to blackberries elicits an adaptive response in the absorption and/or excretion
of flavonoids as assayed by a seven-hour pharmacokinetic challenge. We hypothesized
that there would be an adaptive response in the absorption and excretion of flavonoids
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with repeated exposure to blackberry and that this response will differ between lean
and obese groups volunteers.

5.2

Materials and Methods

5.2.1 Reagents
Analytical standards of cyanidin-3-O-glucoside (Chromadex, Irvine, CA),
epicatechin, and kaempferol-7-O-glucoside (Sigma, St. Louis, MO) were obtained.
Solvents for LC-MS/MS were of mass spectrometry grade and all solvents were at least
analytical grade. Formic acid and triflouroacetic acid were obtained from Sigma-Aldrich
(St. Louis, MO).

5.2.2 Experimental study design and diets
This randomized, controlled, cross-over design study was conducted at the USDA
Beltsville Human Nutrition Research Center (BHNRC; registered at ClinicalTrials.gov#:
NCT01944579). This study (see Figure 19 for study design) received IRB approval (see
Appendix C), and participants provided written informed consent. Inclusion criteria
included those 25-75 years old. Exclusion criteria included: individuals using bloodthinning medications, presence of any gastrointestinal disease, metabolic disease, or
malabsorption syndromes, pregnancy during the previous 12 months, are currently
pregnant or lactating, or plan to become pregnant during the study, Type 2 diabetes
requiring the use of oral antidiabetic agents or insulin, fasting triglycerides greater than
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300 mg/dL, fasting glucose greater than 126 mg/d, use of prescription or over-thecounter antiobesity medications or supplements during and for at least 6 months prior
to the start of the study or a history of a surgical intervention for obesity, active
cardiovascular disease, use of any tobacco products in past 3 months, unwillingness to
abstain from herbal supplements for two weeks prior to the study and during the study,
and known (self-reported) allergy or adverse reaction to blackberries or other study
foods. Participants were provided a controlled diet generated by a registered dietitian
during the length of the study to maintain weight and to provide dietary flavonoids from
blackberry (See Table 14 for detailed meal composition and Figure 18 for macronutrient
composition). Each diet provided approximately 15% energy as protein, 30% energy as
fat, and 55% energy as carbohydrate. Breakfast and dinner meals were required to be
consumed under staff supervision at the research center on weekdays. Blackberries
were a combination of Rubus laciniatus, Rubus Marion, and Rubus fruticosus L.
purchased from SYSCO (Houston, TX). A total of 18 participants including individuals
with normal BMI (n = 7, BMI 20-25) and an obese BMI (n = 11, BMI > 30) were fed a
controlled diet that included either 300 g/d blackberries total, split between breakfast
and dinner meals (treatment) or an isocaloric amount of gelatin (272 g) as the control.
Treatment order was randomized, with half of the participants receiving the control
treatment first over three weeks and the other half blackberries first over three weeks.
A three-week washout period where the participants were instructed to avoid berries
was between treatments. Each participant received the same lot of berries during the
testing day, as described in the pharmacokinetic assessment section below.
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Table 14. Example meal composition of a typical day’s diet provided to participants.a

a) “L” indicates the various “levels” of energy amounts provided to participants to
maintain body weight.
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Figure 18. Macronutrient distribution of a typical day’s diet.
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5.2.3 Pharmacokinetic (PK) assessment
In order to determine the effect of repeated blackberry exposure on flavonoid
bioavailability and metabolism, a pharmacokinetic (PK) assessment was conducted both
three weeks after the participants received the control diet and three weeks after
consuming the diet supplemented with blackberry. During the day of the PK assessment,
volunteers arrived at the beginning of the day at the facilities fasted, produced a
baseline urine, and then consumed 300 g blackberry homogenate within 5 min. Lowflavonoid meals were provided at lunch at dinner times. Blood draws were performed at
0, 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7 h and urine was collected at 0, 1.5, 3, 4.5, 6, and 7
h. After blood was centrifuged at 2560 g for 10 min, 1 mL aliquot of plasma collected
and stabilized with 0.6mL of 0.44 M triflouroacetic acid for anthocyanin analysis, and
another 1 mL plasma aliquot was stabilized with 1% ascorbic acid for flavan-3-ols and
flavonol analysis. Biological samples were stored at -80 °C until analysis.
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Figure 19. Experimental study design for blackberry clinical trial. Lean (BMI 20-25; n = 7)
and obese (BMI > 30; n = 11) participants were recruited for a randomized, cross-over,
controlled feeding study to assess flavonoid pharmacokinetics after a three-week
control period and after a three-week period with 150 g blackberries provided at both
breakfast and dinner meals. A washout period where the participants were instructed to
avoid berries was included between treatments. Pharmacokinetics were assessed from
0-7 h after being placed on a controlled feeding regiment for three weeks containing
either 277 g berry-flavored gelatin (control) or 300 g blackberries daily (containing an
average of 753 mg flavonoids). Plasma and urine were collected during the
pharmacokinetic challenge and analyzed by LC-MS/MS.

5.2.4 Solid phase extraction (SPE)
5.2.4.1 Anthocyanin SPE
Solid phase extraction (SPE) for flavonoids was performed as previously reported
with some modification (Blount et al., 2015). For plasma anthocyanin analysis, 1 mL
plasma was loaded onto a 30 mg Oasis HLB cartridge (Waters Co., Milford, MA) that was
activated with 3 mL MeOH followed by 3 mL H2O. The cartridge was then washed with 2
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mL of 2% formic acid:H2O (v:v), then 1 mL 95:5 H2O:MeOH (v:v), and was finally eluted
with 2 mL 2% formic acid:MeOH (v:v). 10 μL of 10 μM ethyl gallate was added to the
eluate as an internal standard for MS, and this was dried under vacuum (< 50 mm Hg) at
37°C. Residuals were then resolubilized in 100 μL of 2% formic acid:H2O (v:v), sonicated
and vortex-mixed for 10 s each, and then centrifuged at 18,000 g for 5 min before
supernatant was transferred to a 300 µL HPLC vial for analysis. Extraction recovery was
assessed using ethyl gallate and was found to be greater than 95%.
For urine analysis, 10 mL urine was centrifuged for 2 min at 2,000 g to remove
particulates and was then loaded onto a 150 mg Oasis HLB cartridge (Waters, Milford,
MA) that was activated with 6 mL MeOH followed by 6 mL H2O. This was followed by
the cartridge being washed with 4 mL of 2% formic acid:H2O (v:v), 2 mL 95:5 H2O:MeOH
(v:v), and then eluted with 4 mL 2% formic acid:meOH (v:v). 50 μL of 10 μM ethyl gallate
was then added to eluate as an internal standard for MS and was dried under vacuum.
Residuals were then resolubilized as above and centrifuged at 18,000 g for 10 min.
5.2.4.2 Flavan-3-ols and Flavonols SPE
SPE of plasma containing flavan-3-ols and flavonols was the similar as above with
some modification. After plasma was loaded onto a cartridge activated with 1 mL MeOH
followed by 1 mL H2O, the cartridge was washed with 1 mL of 1.5 M formic acid:H2O
(v:v), 1 mL 95:5 H2O:MeOH (v:v), and then was eluted with 2 mL 0.1% formic acid:MeOH
(v:v). Ethyl gallate internal standard was added to the eluate and dried under vacuum.
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Residuals were then resolubilized in 160 μL of 0.1% formic acid:H2O (v:v) + 40 μL of 0.1%
formic acid:ACN (v:v) before continuing procedure as in the section above.
For urine analysis, SPE procedure was identical as the section above except for a few
modifications. 10 mL urine was loaded onto a 150 mg Oasis HLB cartridge that was
activated with 5 mL MeOH followed by 5 mL H2O. The cartridge was then washed with 2
mL of 1.5 M formic acid, 5 mL 95:5 H2O:MeOH (v:v), and then was eluted with 4 mL 2%
formic acid:MeOH (v:v). Ethyl gallate internal standard was added to the eluate and
then dried under vacuum.

5.2.5 LC-MS/MS analysis
Biological samples were initially screened for a various parent compounds and
their methyl, sulfate, and glucuronide metabolites, after which the major metabolites
were followed.
5.2.5.1 Anthocyanin analysis
Parent compounds and metabolites were separated using an Agilent 1200 HPLC
system using a Waters XBridge BEH shield RP-C18 XP 2.1 x 100 mm 2.5µm column
following a 2 µm frit filter. The column and autosampler were maintained at 40 °C and
10 °C, respectively. The flow was set to 0.26 mL/min and mobile phases were A: 2%
formic acid (aq.); B: 0.1% formic acid/acetonitrile. Gradient conditions were 5% B at 0
min, 25% B at 15 min, 30% B at 18 min, 5% B at 19 min, and 5% B at 23.5 min to reset
the gradient.
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5.2.5.2 Flavan-3-ol and flavonol analysis
Flavan-3-ols and flavonols were analyzed similarly as anthocyanins except for a
few differences. Compounds were analyzed in negative mode and different
chromatography conditions are as follows. The flow was set to 0.26 mL/min and mobile
phases were A: 0.1% formic acid (aq.); B: 0.1% formic acid/acetonitrile. Gradient
conditions were 5% B at 0 min, 60% B at 10 min, 95% B at 11 min, 5% B at 12 min, and
hold at 5% B at 22 min to reset the gradient.

5.2.6 LC-MS/MS for flavonoid quantification
Analytes were quantified using liquid chromatography with tandem mass
spectrometry (LS-MS/MS) using an Agilent 6460 triple quadrupole with electrospray
ionization (ESI) operated in negative mode using selected reaction monitoring (SRM)
mass transitions. Injection volume was 10 μL for plasma and 5 μL for urine samples.
Acquisition SRMs for all analytes are listed in Table 15. In addition, both methods
had an SRM for ethyl gallate in negative mode, 197 → 169 m/z for use as an internal
standard for MS. All mass transitions used a dwell time of 200 ms and fragmentor
voltage of 135 V, and collision energy of 17 eV. Source parameters were as follows: gas
temperature = 350 °C, gas flow = 11 L/min, nebulizer pressure = 30 psi, sheath gas
temperature = 350 °C, sheath gas flow = 11 L/min, capillary potential = 3500 V, and
nozzle voltage = 1000 V.
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5.2.7 Limit of detection and quantification
Limit of detection (LOD) was defined as signal-to-noise ratio (S/N) = 3 and limit of
quantification (LOQ) as S/N = 9. LOD for cyanidin-3-O-glc, epicatechin, kaempferol-7-Oglucoside, and quercetin-3-O-glucoside were 0.24 nM, 22.9 nM, 5.1 nM, and 1.5 nM,
respectively. LOQ was 0.72 nM, 68.7 nM, 15.3 nM, and 4.5 nM, respectively. Both values
were obtained by producing serial dilutions of the analyte. Signal-to-noise (S/N) ratio
was calculated using MassHunter software using the peak-to-peak method.

Table 15. Acquisition SRMs for LC-MS/MS.
Compound

MS1

MS2

mode

Peonidin-glucur

477

301

+

Cyanidin-glucur

463

287

+

Peonidin-glc

463

301

+

Cyanidin-3-O-glc

449

287

+

EC-3’-O-glucr

465

289

-

Kaemp-glucr

461

285

-

Kaemp-7-O-glc

447

285

-

Methyl-Kaemp-glucr

475

299

-
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5.2.8 Data analysis
Plasma AUC is expressed as nmol compound∙h and was normalized to body
weight and blood volume. Normal physiological parameters (blood volume/body weight)
vary for obese patients, so an adjusted calculation was used in this case (Lemmens et al.,
2006). Urinary accumulation is expressed at cumulative nmol compound. Since different
lots of blackberries were used throughout the study, data were also normalized on the
basis of flavonoid dose. In addition, a carryover subtraction was performed as to
eliminate bias due to accumulation of flavonoids throughout the blackberry treatment
period. Any non-normally distributed data (as determined by the goodness-of-fit test)
was transformed using the optimum lambda Box-Cox value, after which normality was
again tested. Statistical significance was then determined using a paired t-test. Analysis
was performed using JMP 12 (SAS Institute, Cary, NC), and significance was set at α =
0.05.

5.3

Results

5.3.1 Key flavonoid composition of blackberries
Phenolic composition of blackberries is shown in Table 16. The main anthocyanin
in the blackberries was cyanidin-3-O-glucoside, which is consistent with previous reports
(Kaume et al., 2012; Mertz et al., 2007). Interestingly, the blackberries used in this study
contained greater amounts of kaemperfol glycosides and less quercetin glycosides
compared to previous reports (Mertz et al., 2007), but this variation may be related to
differences in the specific varieties and harvest season.
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5.3.2 Characterization of parent flavonoids and metabolites
Figure 20 displays representative chromatograms of anthocyanins and their
metabolites. In addition to the unmetabolized cyanidin-3-O-glc being identified, methyl
and glucuronide derivatives were also detected. Since native peonidin was not detected
to any great extent in blackberry, the peonidin in circulation is most likely derived from
methylation of cyanidin by Phase II metabolizing systems, such as catechol-Omethyltransferase (COMT). In addition, the presence of the two unresolved peaks likely
indicates methylation at two different sites on the anthocyanin structural backbone.
Figure 21 shows representative chromatograms of flavan-3-ols, flavonols and
their metabolites. As with the anthocyanins, both methyl and glucuronide derivatives of
kaempferol were detected. Presence of epicatechin-3’-O-glucuronide in urine and
plasma was confirmed by comparing retention times to an authentic standard
synthesized using the human UGT1A9 enzyme (Blount et al., 2012) (data not shown).
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Table 16. Composition of key blackberry flavonoids from an example batch.a
Cy-3-O-glc

Catechin

Epicatechin

Batch

Quercetin-gly 1 Quercetin-gly 2

ug/g fresh weight

A

932 ± 48.4 111 ± 7.22

638 ± 43.1

1440 ± 68.3

112 ± 4.66

45.0 ± 2.01

B

585 ± 14.1 135 ± 2.09

637 ± 22.3

910 ± 22.6

54.9 ± 2.18

38.1 ± 1.41

C

555 ± 45.4 157 ± 9.25

739 ± 59.2

919 ± 63.2

75.2 ± 5.15

44.9 ± 3.19

D

322 ± 10.9 45.9 ± 2.60

237 ± 13.5

477 ± 28.7

108 ± 6.13

51.2 ± 2.52

E

617 ± 2.16 99.1 ± 3.98 1100 ± 14.1

982 ± 6.30

87.1 ± 0.362

45.3 ± 7.37

886

87.4

44.9

AVG
a

Kaemp-7-O-glc

602

219

670

Values are expressed average ± SEM (n = 3).

5.3.3 Plasma flavonoid AUC
Figure 22 displays the absorption, metabolism, and excretion of select
anthocyanins detected in plasma over 7 h after a bolus dose of blackberries. Overall,
repeated blackberry treatment appeared alter the absorption and metabolism of select
anthocyanins as indicated by differences in plasma AUC. In comparing specific
treatments, the results showed that there was a statistically significant (P < 0.05)
increase in plasma AUC of peonidin-glc 1 after 3-week blackberry treatment in lean but
not obese participants. Pooling results from peonidin-glc 1 plus 2 plasma AUC, there was
a borderline (P = 0.056) significant increase in these compounds for lean but not obese
participants after blackberry treatment. In comparing differences in flavonoid plasma
AUC due to BMI, a trend (P = 0.099) was observed for greater amounts of plasma
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peonidin-glc 1 in the lean but not obese group after being exposed to blackberry. There
was a stronger trend for the lean group containing higher amounts of cyanidin-3-O-glc in
plasma than the obese population under control conditions (P = 0.076) compared to
after blackberry exposure (P = 0.11). When results from total anthocyanin glucosides are
pooled (cyanidin-3-O-glc plus methylated compounds), there was a subtle trend for
higher circulating amounts of these compounds in the lean compared to the obese
group under both control (P = 0.10) and blackberry (P = 0.11) conditions.
Figure 23 shows the absorption, metabolism, and excretion of flavan-3-ols and
flavonols over 7 h after a bolus dose of blackberries under both control and treatment
conditions. Results mainly showed a trend for higher plasma AUC of pooled kaempferol
and its derivatives (parent compounds and metabolites) in the lean compared to the
obese group after blackberry exposure (P = 0.082), but this trend was less strong for
control (P = 0.19).
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Figure 20. Representative chromatograms of anthocyanins and their metabolites
identified in plasma and urine in positive mode. Peak identification: (a) peonidin-glucr 1;
(b) peonidin-glucr 2; (c) cyanidin-glucr; (d) peonidin-glc 1 (e) peonidin-glc 2; (f) cyanidin3-glc.
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Figure 21. Representative chromatograms of flavan-3-ols, flavonols and their
metabolites identified in plasma and urine in negative mode. Peak identification: (a)
Epicatechin-3’-O-glucr; (b) Kaempferol-O-glucr; (c) Kaempferol-7-O-glc; (d) methylKaempferol-O-glucr.
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Figure 22. Absorption, metabolism, and excretion of anthocyanins after a bolus dose of
blackberries. An acute pharmacokinetic assessment determined anthocyanin
appearance in plasma and accumulation in urine over 7 h in both lean (n = 7) and obese
(n = 11) populations. Data are displayed as average ± SEM. Box plots display
interquartile range, median, and average as represented by an “x.” *P < 0.05.
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Figure 22, con’d.
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Figure 22, con’d.
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Figure 22, con’d.
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Figure 23. Absorption, metabolism, and excretion of flavan-3-ols and flavonols after a
bolus dose of blackberries. An acute pharmacokinetic assessment determined flavan-3ol and flavonol appearance in plasma and accumulation in urine over 7 h in both lean (n
= 7) and obese (n = 11) populations. Data are displayed as average ± SEM. Box plots
display interquartile range, median, and average as represented by an “x.” *P < 0.05.

138

Figure 23, con’d.
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Figure 24. Absorption, metabolism, and excretion of total flavonoids (all analytes) after a
bolus dose of blackberries. An acute pharmacokinetic assessment determined flavonoid
appearance in plasma and accumulation in urine over 7 h in both lean (n = 7) and obese
(n = 11) populations. Data are displayed as average ± SEM. Box plots display
interquartile range, median, and average as represented by an “x.” *P < 0.05.
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5.3.4 Flavonoid accumulation in urine
Supporting results observed in plasma, there were differences in absorption and
metabolism of select anthocyanins with BMI as indicated by clearance and accumulation
of these compounds in urine (see Figures 22, 23 and 24). For individual anthocyanins,
there was a trend for the lean group to have greater urinary accumulation of cyanidin-3O-glc than obese volunteers under both control (P = 0.079) and blackberry treatment (P
= 0.068) conditions. In addition, there was a trend for greater amounts of urinary
peonidin-glc 2 in the lean compared to the obese group under both control (P = 0.056)
and blackberry treatments (P = 0.059). There was significantly greater total anthocyanin
metabolite urinary accumulation in lean compared to obese volunteers after blackberry
treatment (P = 0.015) but not under control conditions (P = 0.074). Finally, when results
for all anthocyanins were pooled, there was significantly greater urinary accumulation in
lean compared to obese participants with blackberry exposure (P = 0.016) but not under
control conditions (P = 0.081).
For kaempferol-7-O-glycoside, there was significantly greater urinary
accumulation in lean compared to the obese volunteers under both control (P = 0.013)
and blackberry (P = 0.011) conditions. No differences in epicatechin metabolism was
observed with blackberry treatment or BMI. Interestingly, when data from all analytes
(total flavonoids) are pooled, there was significantly greater urinary accumulation in
lean compared to obese participants under control (P = 0.037) but not blackberry
conditions (P = 0.17). There were no statistically significant differences when comparing
differences in urinary accumulation before and after blackberry treatment within groups.
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5.4

Discussion

Though the experimental paradigm of an acute PK assessment is most commonly
used to measure the bioavailability of flavonoids and other bioactive compounds, data
resulting from these acute experiments may not be representative of chronic dietary
exposures to flavonoids occurring in broader populations. For instance, a clinical study
with a two week run-in period providing 800 mg EGCG per day resulted in an
approximately 60% increase in plasma AUC compared to those not exposed to EGCG
(Chow et al., 2003). An additional clinical trial detected increases in circulating and
excreted flavan-3-ols after 7-day repeated exposure to tea (Fung et al., 2013), though
these results were not corrected for accumulation as in the present study. Our results
showed differences in the absorption and metabolism of select anthocyanins with a 57%
increase in the average plasma AUC of a methylated cyandin derivative (peonidin-glc 1)
in lean participants after blackberry treatment, in addition to a trend for increased
amounts of total methylated cyanidin derivatives (peonidin-glc 1 plus 2) in the plasma of
this same group.
In contrast, Jean et al. (2012) study found no difference in cyanidin-3-O-gluoside
plasma AUC after participants were given 1 g of black bean seed coat extract daily for
two weeks (Jeon et al., 2012). However, Jeon et al. only measured cyanidin-3-Oglucoside and therefore these results may not have captured likely shifts in the
metabolism of this anthocyanin after the period of repeated exposure. In addition, our
study did not utilize isolated anthocyanins, but rather a whole food, which generally
results in lower absorption, and potentially reduced metabolism, compared to isolated
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flavonoids (Clifford et al., 2013). These differences in experimental design may also
indicate that adaptation in absorption and metabolism may differ depending on
whether a flavonoid is provided in a purified/extract form or in the context of a diet
which may result in interactions between food macro- and micronutrients (Bordenave
et al., 2014; Guo et al., 2013; Peters et al., 2010), in addition to synergistic properties of
flavonoid mixtures (Tagashira et al., 2012). Ultimately, it is crucial to consider absorption
and metabolism of these compounds in the context of a whole food, where there can be
multiple interactions between food components and flavonoids (Zhang et al., 2004; Zhu
et al., 2008).
Our data appear to demonstrate differential adaptation in the metabolism of
anthocyanins with repeated exposure to blackberry between lean and obese subjects.
For example, there was significantly greater total anthocyanin metabolite urinary
accumulation in lean compared to obese volunteers after blackberry treatment, while
there was no difference under control conditions. In contrast, there was no statistically
significant difference in urinary accumulation of unmetabolized cyanidin-3-O-glc
between groups after blackberry treatment or during the control period. Thus, the
increase in the accumulation of anthocyanin metabolites in lean but not obese
participants after blackberry exposure may indicate Phase II systems being differentially
induced with repeated exposure due to BMI. Though there may be differences in urinary
output, the values presented are volume corrected. The lack of a similar shift in the
anthocyanin metabolites of the obese group may support the notion of a fundamental
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difference in the metabolism of these compounds in various disease states such as
obesity and diabetes (Xiao and Högger, 2014).
The metabolites detected in this study align with previous reports that observed
key Phase II metabolites of anthocyanins as the methyl and glucuronide derivatives,
especially those found in urine (Felgines et al., 2005). In addition, a tracer study that
provided 13C-labeled cyanidin-3-O-glucoside to humans volunteers reported similar
Phase II metabolites as identified in the present study, namely the glucuronide and
methyl glucuronide metabolites (Czank et al., 2013; de Ferrars et al., 2014). Finally, a
study that provided an acute dose of 200 g of blackberries to humans observed
glucuronide and methyl glucuronides as the major Phase II metabolites (Felgines et al.,
2005), which corresponds with our analysis.
In regards to the metabolite profile, it appears that there is greater interindividual variability in the metabolite concentrations with repeated exposure to
blackberry, especially in regards to the anthocyanins (see box plots in Figure 22, 23, 24).
This variability in metabolites appears to indicate differences in the adaptive response,
which may reflect genetic polymorphisms in the xenobiotic metabolizing systems that
result in a system more or less susceptible to induction (Ramos et al., 2014).
Experiments reported in Chapters 4 and 5 of this dissertation modeled the
repeated exposure paradigm in humans intestinal Caco-2 cells to determine whether
adaptation in flavonoid transport and metabolism occurred with repeated exposure.
Chapter 4 demonstrated that pretreatment with isolated flavan-3-ols increased
appearance of methylated derivatives, which corresponds to the increases in peonidin
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levels observed in plasma with repeated exposure. Additionally, there were increases in
transport of select flavan-3-ols when cell monolayers were pretreated with tea and
grape seed extracts. In Chapter 5, experiments utilized a composite blackberry extract
produced from the berries used in this clinical study. Interestingly, pretreatment with
the extract overall resulted in decreased transport of flavonoids, though we were
unable to detect metabolites in this model. Analysis of gene expression data of key
transport and metabolizing systems revealed alterations with repeated blackberry
exposure, indicating that the gut may potentially be a driver of differences observed in
absorption and metabolism of flavonoids.
Though the mechanisms behind these adaptive phenomena are not well
understood, it is known that the intestinal enterocytes have a high turnover rate and
the nascent cells repopulating the epithelial lining can be influenced by the extracellular
matrix (Reya and Clevers, 2005). Thus it is possible that dietary factors including
flavonoids can influence the differentiating cell’s function leading to altered
bioavailability. Supporting this notion are in vitro, cell-based data demonstrating that
Caco-2 cell monolayers undergoing repeated treatment with flavonoid-rich extracts of
grape products during the differentiation process exhibit altered markers of
differentiation (Laurent et al., 2004, 2005). Additionally, transport systems such as OAT
(organic anion transporters) in liver tissue can be altered by long-term treatment of
anthocyanins (Riha et al., 2015). Thus, there are likely alterations occurring at the
molecular level over a 3-week period that may relate to the the observed differences in
the absorption and metabolism of these flavonoids. Although the exact tissue-level

145
alterations are yet unknown, the gut and liver are potential candidates since they are
major sites of metabolism and transport of these compounds.
In contrast to previous literature that observed adaptation to extracts rich in
flavan-3-ols in rodent models (Ferruzzi et al., 2009; Wang et al., 2012), the present study
did not observe significant differences in plasma AUC or urinary accumulation of
epicatechin metabolites with repeated exposure to blackberry. Lack of an adaptive
response may be due to differences food matrix, interactions between flavonoids, or
phylogenetics. In addition, the differing doses need to be considered as the amount of
epicatechin in blackberry (approximately 0.6 mg/g) was relatively low compared to that
of grape seed extracts which can contain up to approximately 60 mg/g epicatechin
(Villani et al., 2015). Still, because of the relatively small amount of participants in this
study (n = 18) differences that are not significant should be taken with caution. The
study appears to be statistical underpowered as a post-hoc power analysis reveals that
at least 38 participants would be needed to detect significance differences in lean and
obese cyanidin-3-O-glc appearance in urine.
Though anthocyanins are considered to have the lowest oral bioavailability of the
flavonoids when solely considering the parent compound, in fact, they have a much
higher systemic bioavailability (approximately 20%) when considering both Phase II and
microbial metabolites of these compounds (Czank et al., 2013). In the present study, we
focused on the parent compounds and their Phase II metabolites although some studies
using animal models report that gut microbiota adapts with repeated exposure to
flavonoids and other phenolics (Wang et al., 2015). These bacterial metabolites should
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be considered in future studies as the production of these compounds likely changes in
humans with repeated exposure to flavonoids.
Strengths of this study include its controlled, randomized, cross-over design. Also,
possible variation in flavonoid absorption due to of differences in background diet were
reduced through standardization of the diet in the three weeks leading up to the PK
assessment. One of the study’s limitations include its relatively short duration since
broad dietary patterns are generally longer than this period of time. In addition, our
small sample size may have decreased the ability to detect differences. Though we
tracked parent flavonoids and their Phase II metabolites, shifts in gut microbial
populations through diet modifications may result in increased production of lowmolecular weight flavonoid catabolites that are not accounted for in the current analysis.

5.5

Conclusion

While pharmacokinetic assessments used in determining the bioavailability of
flavonoids have typically been performed using a paradigm of acute oral doses, the
current findings suggest that adaptation in absorption and metabolism of select
flavonoids may occur over three weeks of repeated exposure to blackberry as part of a
mixed diet. The present study showed that in lean but not obese individuals, plasma
AUC of methylated derivatives (peonidin-glc) of cyanidin-3-O-glc increased after
repeated exposure to blackberry. In addition, metabolism of flavonoids appeared to
differ based on the BMI of the individual, as this study observed increased urinary
accumulation of anthocyanin metabolites in lean but not obese individuals after
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undergoing repeated exposure to blackberry. Further research should continue to
characterize this adaptive effect to isolate specific molecular mechanisms and locations
(gut, liver, etc) for these phenomena in order to better leverage these findings for the
purposes of optimizing delivery and dietary recommendations consistent with
prevention of chronic disease. These data also help inform recommendations for the
increasingly common issue of obesity in both industrialized and even developing
countries, since this population may have altered metabolism of flavonoids. Additionally,
results suggest that further knowledge of adaptation to repeated exposure of flavonoidrich foods may better inform our understanding of the true extent of the bioavailability
of these compounds and dietary/physiological factors that impact these measures.
Taken together, these data demonstrate that repeated exposure to flavonoid-rich foods
more consistent with their inclusion in a longer term dietary patterns may lead to a
different bioavailabilities for individual flavonoids compared to those observed from a
single acute dose.
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CHAPTER 6.

CONCLUSIONS AND FUTURE DIRECTIONS

6.1

Overall Conclusion

Though consumption of foods rich in flavonoids including beverages and fruits
such as tea, grape, and berries have been associated with decreased risk of various
chronic diseases, application for chronic disease prevention has been argued to be
limited since their acute oral bioavailability is low (less than 5%). Still, chronic dosing
paradigms have been reported to increase systemic bioavailability of flavonoids in both
animal (Ferruzzi et al., 2009; Wang et al., 2012) and human models (Chow et al., 2003).
Characterization of the absorption and metabolism of flavonoid-rich foods and the
factors that influence bioavailability are essential in order to correlate epidemiological
observations to chronic disease preventative endpoints. This dissertation aimed to fill
the knowledge gap with special focus on adaptive phenomena that influence
bioavailability of flavonoids such that it can be leveraged for maximizing flavonoid
bioavailability. More specifically, it aimed to model adaptive phenomena observed in
vivo by utilizing an in vitro, cell-based model of the small intestinal epithelial cells in
order to determine alterations occurring at the gut level from repeated exposure to
flavonoids in addition to characterizing metabolites that result from xenobiotic
metabolism of flavan-3-ols such as from tea and grape seed.
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First, the circulating flavan-3-ol metabolite profile of rodents administered grape
seed was elucidated through a combination of our collaborators supplying us with
enzymatically-synthesized flavan-3-ols metabolites combined with our use of NMR and
MS to characterize the structure of these compounds. To summarize, Chapter 2
concluded that the flavan-3-ols metabolites appearing in rodent plasma could be
matched with enzymatically synthesized glucuronide and methyl glucuronide flavan-3-ol
metabolites. By using 1D and 2D NMR spectroscopy, we showed that methylation
occurs at the 3’ position of both catechin and epicatechin and that major sites of
glucuronides occur at the 5 and 7 positions. In addition, a two-site laboratory validation
demonstrated that the analytical method we developed were robust across instruments
and personnel. Interestingly, we also identified a large difference in the mass
spectrometry analysis response factor between the parent compound and glucuronide
metabolites of flavan-3-ols, which may lead to an overestimation of these metabolites in
biological samples and is not regularly accounted for in these types of analyses.
Once the chemical structure of the circulating flavan-3-ol metabolites found in
rodents administered grape seed extract was determined, we turned to the research
performed in Chapter 3 that highlighted the effect of chronic exposure of the isolated
flavan-3-ols EGCG and EC in addition to tea and grape seed extracts rich in flavan-3-ols
on their intestinal transport using the Caco-2 intestinal cell culture model. We
concluded that repeated low-dose (1-10 µM) exposure to these compounds and
extracts during the cell differentiation period increased transport of these compounds
and altered its metabolite profile. Interestingly, treatment with these extracts also
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appeared to affect the barrier function of the cell model. Limitations of this model is
that it considers only the gut as an agent of flavonoid bioavailability and metabolism, in
addition to that metabolites were not detectable when using enriched extracts.
Given that chronic exposure to isolated flavan-3-ols and enriched extracts were able to
affect their intestinal transport and metabolism, we turned to probing additional classes
of flavonoids and phenolic acids by utilizing blackberry extract. We used a similar
chronic dosing paradigm as described in Chapter 3 to test if low dose exposure resulted
in differences in transport of the various phenolic compounds. We interestingly
observed an overall decrease in the transport of the parent compounds with repeated
exposure, though we were unable to detect the metabolites. Gene expression analysis
of the xenobiotic metabolizing and transport systems indicated an overall decrease in a
majority of these systems, which correlated to the decreases in transport of select
flavonoids and phenolic acids. As in the limitations in the previous chapter, we were not
able to detect metabolites using this model but the utility of this model is still apparent.
Taken together, Chapter 3 and 4 suggest that gut adaptation to flavonoids may
be class specific and dependent on matrix and interactions between flavonoids. For
instance, tea and grape contain largely monomeric and polymeric flavan-3-ols, while
berries contain large amounts of anthocyanins, flavonols, and phenolic acids. This
deserves further investigation as knowledge of differences in adaptation to specific
classes of flavonoids and food helps determine factors that influence adaptive
responses in humans.

151
Finally, we performed a clinical study to characterize in vivo adaptation by
determining the effect of repeated 3-week exposure to blackberry fruit on the
absorption and metabolism of flavonoids, in addition to determining any effect of BMI
on these endpoints. Chapter 5 concluded that adaptation in bioavailability and
metabolism in humans occurs after 3-week daily exposure to flavonoid-rich blackberry.
The amount of blackberries administered in the study was 300 g or approximately 4
servings of fruit, which was divided between breakfast and dinner meals. The amount of
berries given at the PK assessment (300 g) is approximately that recommended by the
2015 Dietary Guidelines for Americans. Anthocyanins, flavan-3-ol, and flavonol parent
compounds and metabolites were the major flavonoids detected in circulation and
found accumulated in urine. Plasma AUC of methylated cyanidin-3-O-glc derivatives
increased after chronic exposure, possibly indicating induction of metabolizing enzyme
systems. Interestingly, epicatechin-3’-O-glucr appearance in plasma or its accumulation
in urine did not appear to be influenced by either blackberry exposure or BMI, which is
in contrast to previous animal work. This may be due to several factors, including
differences between humans and rodents, along with dosage and food matrix.
In conclusion, bioavailability of select flavonoids from blackberries appears to
change based on previous exposure to these compounds, in addition, the adaptive
response and absolute bioavailability of these compounds may be influenced by BMI.
This is of interest because of the large increase in the incidence of obesity in both
industrialized and developing countries and thus may affect recommendations for these
compounds. However, for some specific classes of flavonoids, such as flavan-3-ols,
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bioavailability and metabolism may not be as negatively affected compared to other
classes. This may be a reflection of differences in specific transport and metabolizing
systems these compounds undergo. When comparing results from the in vitro data from
the Caco-2 model to the in vivo data, there are some correlation but also differences.
Flavan-3-ols from the tea and grape chronic treatment displayed increases in transport,
and pure compounds generally showed increases in metabolism. In contrast, results
from blackberry treatment did diverge slightly from this, showing decreases in transport
of parent compounds. However, this model was limited since we were not able to
detect metabolites, so any shift in metabolism would not be captured.

6.2

Future Directions

Our data demonstrated that adaptation can occur in humans and that the gut
likely plays a vital part in the alterations that occur with repeated exposure. While the
data is promising, the speculation on the mechanism of whether adaptation in the
absorption and metabolism of flavonoids in humans are entirely due to the gut needs
further investigation. In addition, the effect of the obese condition on the mechanisms
of flavonoid absorption and metabolism needs to be further characterized. It has been
shown that impaired insulin signaling that can occur with obesity may alter expression
of drug metabolizing enzymes responsible for glucuronidation and sulfation of flavonoid
metabolites (Kim and Novak 2007). This change in activity of Phase II metabolizing
enzymes is likely to alter the generation of conjugated flavonoid metabolites. It will be
interesting to further explore whether the function of these xenobiotic systems are
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compromised in obese populations. Future work can incorporate additional aspects of
human physiology into our reductionist model of the small intestine epithelia to
generate a more complex model since xenobiotic metabolism involves more than the
gut, with the liver and kidney also playing integral roles. Finally, changes in the
absorption and metabolism of these compounds is especially interesting in potential
biomarkers of intake. If these markers produce robust responses and differences
between individuals who are habitual versus sporadic consumers, there is more
potential for candidate markers to be identified and used in large epidemiological
studies.
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Appendix A

Weekly Meal Composition for Blackberry Study

Appendix Table A. 1. Example meal composition for study participants during controlled
feeding periods.

*Note: The “L” number is based upon the participant’s daily energy needs.
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Appendix Figure A. 1. Macronutrient distribution of an example meal for study
participants during controlled feeding periods.
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Appendix B

Flavonoid Stabilization Procedure for Urine and Plasma

Human Plasma acidification protocol for Stabilizing (non-anthocyanin) Flavonoids


Freshly prepare 1% ascorbic acid/water (weight:volume) by dissolving 10 g Lascorbic acid (catalogue# A92902, Sigma-Aldrich) into 1 L of nanopure water



Aliquot 250 μL of ascorbic acid solution into each 2 mL EDTA-cyrovial, keeping
vials cold on ice



Aliquot 1 mL of plasma into vial with the ascorbic acid solution



Transfer plasma to -80°C
Human Plasma acidification protocol for Stabilizing Anthocyanins



Prepare a 12.5% (v/v) formic acid (catalogue# 695076 Sigma-Aldrich) solution by
bringing 125 mL formic acid up to 1 L with nanopure water



Aliquot 120 μL of 12.5% formic acid solution into each 2 mL EDTA-cyrovial,
keeping vials cold on ice



Aliquot 1 mL of plasma into vial with the formic solution



Transfer plasma to -80°C
Human Urine acidification protocol for Stabilizing All Flavonoids



Prepare a 1% (v/v) formic acid (catalogue# 695076 Sigma-Aldrich) solution by
bringing 10 mL formic acid up to 1 L with nanopure water



Dilute urine at a ratio of 1:5 1% formic acid:urine



Transfer urine to -80°C
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Appendix C

IRB Consent Form for Blackberry Clinical Study
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